The impact of a controlled 10-week pistachio feeding crossover trial on blood lipids and measures of adiposity by Bushnell, Alison Helen
 THE IMPACT OF A CONTROLLED 10-WEEK PISTACHIO FEEDING 
CROSSOVER TRIAL ON BLOOD LIPIDS AND MEASURES  
OF ADIPOSITY 
 
 
 
 
 
 
A Thesis 
 
presented to 
 
the Faculty of California Polytechnic State University, 
 
San Luis Obispo 
 
 
 
 
 
 
In Partial Fulfillment 
 
of the Requirements for the Degree 
 
Master of Science in Agriculture 
 
with a Specialization in Food Science and Nutrition 
 
 
 
 
 
 
 
by 
 
Alison Helen Bushnell 
 
June 2015 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 
Alison Helen Bushnell 
ALL RIGHTS RESERVED 
iii 
 
COMMITTEE MEMBERSHIP 
 
 
TITLE: The impact of a controlled 10-week pistachio 
feeding crossover trial on blood lipids and 
measures of adiposity 
 
 
 
AUTHOR: Alison Helen Bushnell 
 
 
 
DATE SUBMITTED: June 2015 
 
 
 
 
 
 
 
COMMITTEE CHAIR:  Aydin Nazmi, Ph.D., Associate Professor, 
Food Science and Nutrition Department and  
 Director of STRIDE, California Polytechnic 
State University, San Luis Obispo 
 
 
COMMITTEE MEMBER: Laura Hall, Ph.D., RD 
 
 
COMMITTEE MEMBER: Soma Roy, Ph.D., Associate Professor, 
Statistics Department, California Polytechnic 
State University, San Luis Obispo 
 
 
 
 
 
 
iv 
 
ABSTRACT 
The impact of a controlled 10-week pistachio feeding crossover trial on blood lipids 
and measures of adiposity 
 
Alison Helen Bushnell 
 
 
 Cardiovascular disease (CVD) is the leading cause of death in the United 
States and has negative impacts at both the individual- and population-level through 
reduced quality of life, economic burden, and strain on the healthcare system.  
Dietary modifications, such as pistachio consumption, may help prevent CVD and 
two of its leading risk factors: dyslipidemia and overweight/obesity.  The objective 
of this study was to determine the effects of pistachio consumption (20% daily 
energy need) on measures of adiposity and blood lipids in healthy young adult 
females.  This study utilized 10-week crossover feeding trials at California 
Polytechnic State University, San Luis Obispo (CP-SLO) and California State 
Polytechnic University, Pomona (CP-P).  Participants (n=48, mean age 21 ± 0.51 
years) served as their own controls.  Mean body mass index (BMI) was 21.9 ± 2.32 
kg/m2 and mean total cholesterol (TC) was 155.0 ± 27.7 mg/dL.  Pistachio diet 
participants consumed 20% of their daily energy needs of pistachios each day, 
whereas control diet participants maintained their usual diet without consuming nuts.  
The two diet treatments were separated by a 15-week washout period during which 
all participants resumed their usual diets.  No significant differences were found 
between diet treatments for triacylglycerols (TAG) (p=0.6), TC (p=0.5), low-density 
lipoprotein cholesterol (LDL-C) (p=0.4), high-density lipoprotein cholesterol (HDL-
C) (p=0.9), TC/HDL-C (p=0.7), body weight (p=0.8), BMI (p=0.9), waist 
circumference (WC) (p=0.4), or total body fat percentage (p=0.9).  Likewise, no 
significant differences were found during the pistachio treatment or during the 
control treatment for any measured variable.  Strengths of this study were the 
crossover design, utilization of dual-energy x-ray absorptiometry (DXA) for precise 
body composition measurements, and the use of individually measured bags of 
pistachios to help with compliance.  Limitations of the study included the relatively 
small sample size and short intervention period.  Pistachio supplementation was not 
associated with significant changes in measures of adiposity or the lipid profile.  
Longer interventions with more participants are needed to test the long-term effects 
of pistachio consumption with greater power to detect differences.   
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CHAPTER 1: INTRODUCTION 
Cardiovascular disease (CVD) is the number one cause of death in the United 
States, responsible for approximately 1 in every 4 deaths (Kochanek, Xu, Murphy, 
Miniño, & Kung, 2009).  More than 83 million Americans live with at least one form of 
CVD and far more are at risk due to pre-existing risk factors.  One of the most powerful 
risk factors, dyslipidemia, affects 71 million adults, two thirds of whom do not have their 
condition under control (Centers for Disease Control and Prevention, 2010).  Another risk 
factor, obesity, affects one third of adults and 17% of children (Ogden, Carroll, Kit, & 
Flegal, 2014).  The individual- and population-level consequences of CVD include 
diminished quality of life, increased risk of death, and economic burden. 
Patients with CVD may have debilitating physical problems, psychological 
problems, or difficulty with social interaction in addition to an increased risk of death.  
Mortality and morbidity are increased in all age categories of CVD patients leading to 
elevated health care costs.  Annually, CVD costs the United States $306.12 billion in 
health care and lost productivity, which equates to 1 out of every 6 dollars spent on health 
care (Heidenreich et al., 2011).  As the population ages, even greater stress will be placed 
on the healthcare system (Odden et al., 2011).  Thus, it is critical to address the causes of 
CVD through prevention strategies at the individual and population levels.    
Diet affects a multitude of variables related to cardiovascular health.  The Centers 
for Disease Control and Prevention (2013) recently found that more than 200,000 CVD 
deaths each year may be prevented by modifying dietary and physical activity behavior.  
Dietary behavior strongly influences measures of adiposity and lipid status, which are 
both strong risk factors for CVD.  Excess weight is associated with CVD, hypertension, 
hypercholesterolemia, diabetes, and cancer (Bray, 2004).  Similarly, dyslipidemia is 
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linked closely with hypertension and is a powerful indicator of atherosclerosis (Hsu et al., 
2013).    
Plant-based diets, which emphasize fruits, vegetables, nuts, and other minimally 
processed foods, may help lower body mass index (BMI), blood pressure, and cholesterol 
levels (Tuso, Ismail, Ha, & Bartolotto, 2013).  Nuts are naturally high in healthy fats, 
protein, and other beneficial nutrients (Alexiadou & Katsilambros, 2011).  Pistachios in 
particular have many unique nutritional properties and contain fewer calories per serving 
than any other nut (Dreher, 2012).  Consequently, they have been the topic of many 
recent studies.   
Previous research has found that pistachio consumption improves lipid profile and 
decreases CVD risk (Aldemir, Okulu, Neselioglu, Erel, & Kayigil, 2011; Baer, Gebauer, 
& Novotny, 2012; Edwards, Kwaw, Matud, & Kurtz, 1999; Gebauer, West, Kay, 
Alaupovic, Bagshaw, & Kris-Etherton, 2008; Gulati, Misra, Randey, Bhatt, & Saluja, 
2014; Kocygit, Koylu, & Keles, 2006; Li et al., 2010; Sari et al., 2010; Sheridan, Cooper, 
Erario, & Cheifetz, 2007; Wang, Li, Liu, Ly, & Yang, 2012), but research evaluating 
pistachios’ effects on lipid status has largely focused on unhealthy populations.  None of 
the studies that have investigated the effects of pistachio consumption on measures of 
adiposity (Aldemir et al., 2011; Edwards et al., 1999; Gebauer et al., 2008; Gulati et al., 
2014; Kocygit et al., 2006; Li et al., 2010; Sari et al., 2010; Sheridan et al., 2007; Wang 
et al., 2012) have utilized dual-energy x-ray absorptiometry (DXA), the current gold 
standard to analyze body composition and fat distribution (Fowke & Matthews, 2010).  
There is a conspicuous gap in the scientific literature regarding the effects of pistachio 
consumption on lipid status and measures of adiposity in healthy populations.   
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The objective of this study is to determine the impact of pistachio consumption on 
lipid status and measures of adiposity among healthy young adult females using a 
crossover design with two 10-week treatment periods: a pistachio diet (20% of kcals) and 
a no-pistachio control diet.   It is hypothesized that daily pistachio consumption will help 
improve lipid status and have little or no effect on measures of adiposity.    
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CHAPTER 2: LITERATURE REVIEW 
 Cardiovascular Disease  
Introduction 
 Thirty-five percent of all deaths in the United States are a result of CVD, which is 
equal to 2,300 lives lost every day or one life every 39 seconds (Lloyd-Jones et al., 2009).  
Currently, 1 in every 3 Americans has one or more forms of CVD for a total of nearly 81 
million people (Lloyd-Jones et al., 2009).  Unless improvements are made in prevention 
and treatment, it is projected that the percentage of people with CVD in the United States 
will increase from 36.9% in 2011 to 40.5% by 2030 (Heidenreich et al., 2011).  
Atherosclerosis, which causes CVD, occurs when the walls of vessels thicken and lose 
elasticity, resulting in narrowing of the lumen of the vessel due to plaque build up.  The 
American Heart Association (AHA) estimates that more than 12 million individuals are 
affected by atherosclerosis, which results in more than a half a million deaths every year 
(Go et al., 2014).  Thus, prevention strategies must focus on reducing the number of 
people affected by CVD.   
 
Impacts of Cardiovascular Disease  
 CVD has negative impacts both at the individual and population levels.  
Individuals are physically, psychologically, and economically affected.  Meanwhile, 
disease at the population level leads to a massive economic burden and unsustainable 
stress on the healthcare system.   
Individual Level 
According to the World Health Organization (WHO) (1997), quality of life is 
defined as “The individual’s perceptions of their position in life in the context of the 
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culture and value systems in which they live and in relation to their goals, expectations, 
standards, and concerns.” Quality of life is a multi-factorial concept that includes 
physical and psychological health as well as the ability to have independence and 
functioning social relationships.  Individual economic status can also contribute to overall 
quality of life indicators.   
One of the most common physical symptoms of coronary heart disease (CHD), 
one of the main manifestations of CVD, is angina, which occurs when blood flow to one 
area of the heart is blocked, resulting in a lack of oxygenated blood traveling to that area.  
Angina may occur either at rest or during physical stress and manifests as chest pain that 
may radiate to the arms or neck; however, angina may also lead to indigestion, nausea, 
vomiting, sweating, shortness of breath, weakness, or fatigue (U.S. Department of Health 
and Human Services, 2011).  Intermittent claudication, which results in cramping in the 
calf, thigh, buttocks, or feet during physical activity, is also common with some forms of 
CVD.  Because physical activity increases such symptoms, individuals may 
unintentionally or intentionally alter their pattern of physical activity (Jude & Gibbons, 
2005).  A number of other symptoms, including pulmonary congestion, fatigue, loss of 
appetite, heart palpitations, dyspnea, edema, headache, orthopnea, and flushed face are 
evident with some forms of CVD.  Any one of these symptoms has the potential to 
greatly reduce an individual’s ability to conduct their activities of daily life and as such 
may lead to a decrease in quality of life (Vader & Drazner, 2009).   
 One of the most common psychological problems associated with CVD, and CHD 
in particular, is depression (Stapelberg, Neumann, Shum, McConnell, & Halmilton-
Craig, 2011).  The prevalence of major depression in CHD patients is between 15% and 
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23% in comparison to 4.6% in the general population (Brotman, Golden, & Wittstein, 
2007).  Among people with CHD, depression and/or anxiety may lead to decreased 
quality of life.  Coronary heart disease can be difficult for patients as well as their family 
members and often causes anxiety and depression in both groups due to physical and 
psychological barriers (Reid, Ski, & Thompson, 2013). 
 Coronary heart disease outcomes such as myocardial infarction (MI) impose 
greater restrictions on patients and further reduce quality of life.  Patients who have 
suffered from a MI show greater psychological distress, lower self-esteem, and difficulty 
functioning in social or occupational capacities (Brown, Munford, & Munford, 1993).  
Rates of major depression have been found to be as high as 20% in patients suffering a 
MI and rates of anxiety as high as 30% to 40%.  Likewise, depression increases the risk 
of death or new cardiovascular events by 1.5 to 2 times in CHD patients (Nicholson, 
Kuper, & Hemingway, 2006), and by 36% in CHD patients with anxiety (Roest, Martens, 
Denollet, & De Jonge, 2010).   
 Depression associated with CHD may be attributed to a lack of physical function, 
limited social support, or feelings of inadequacy in patients not able to provide for their 
families.  Among post-MI patients with a lack of emotional support, cardiac events are 
nearly three times as likely (Stapelberg et al., 2011).  Additionally, half of participants in 
a cohort study of patients with CHD admitted being unhappy in their lives in part due to 
their physical limitations.  The consequences of a decreased perception of quality of life 
can be substantial.  Among those who have experienced a cardiac event, depression can 
increase the risk of a subsequent cardiac event or death by 300% to 400% (Simmonds et 
al., 2013). 
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Cardiovascular disease affects individuals financially in the short term and the 
long term.  Short-term costs are those associated with hospitalizations including 
ambulance rides, diagnostic testing, inpatient care, and immediate procedures like 
surgery.  Long-term costs include the price of prescription medications; doctor 
appointments and medical tests; and lost productivity and income (indirect costs) related 
to an inability to work (DeVol & Bedroussian, 2007).  Among individuals with CVD, 
74.8% reported having expenses related to prescription medications, 65% reported 
expenses associated with outpatient care, and 13% reported expenses related to 
emergency or inpatient services (Uberoi & Cohen, 2012).  Individuals with CVD have an 
average total medical expenditure of $7,026 per year compared to only $1,884 in 
individuals with no chronic conditions (Uberoi & Cohen, 2012).  Additionally, in adults 
with CVD plus other chronic conditions, average total medical expenditure more than 
doubles to $14,627 per year (Uberoi & Cohen, 2012).   
In sum, the individual-level physical, psychological, and economic burdens 
associated with CVD are wide ranging and negatively impact quality of life indicators for 
patients and their families. 
Population Level 
 The aging population in the United States is predicted to put great stress on the 
healthcare system in the coming decades.  Because medical costs continue to rise, the 
effects of the aging population on an already overburdened healthcare system is 
worrisome.  As a result of greater life expectancy and the “Baby Boom” following World 
War II the number of adults entering into older age is set to increase in coming years.  
From 2011 to 2040 the number of adults aged 65 years and older living in the United 
States will increase nearly 200% from 41.4 million to 79.7 million (Centers for Disease 
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Control and Prevention, 2003).  During the same timeframe the population ages 85 years 
and older is expected to rise from 5.7 million to 14.1 million (Figure 1) (U.S. 
Department of Health and Human Services, 2012).  Because chronic diseases 
disproportionately affect the elderly, the population increase in older adults will 
significantly impact the prevalence, incidence, and overall cost of CVD (Odden et al., 
2011).   
 
 
Figure 1.  Projected number of adults !65 years and !85 years living in the United 
States between 2011 and 2040, adapted from (Odden et al., 2011).   
 
Coronary heart disease, in particular, is most prevalent in the elderly and will increase the 
need for both preventative efforts and treatments in the future.  This need is associated 
with an increased burden on hospitals and medical personnel as well as public health 
departments and training institutions.  Not only is the number of new cases of CHD 
estimated to increase by 25% from 2010 to 2040, but the number of deaths from CHD is 
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also projected to increase by more than 50% during the same timeframe (Figure 2) 
(Odden et al., 2011).   
 
 
Figure 2.  Projected mortality from coronary heart disease in adults 35-64 years and 
adults 65-84 years in 2010, 2020, 2030, and 2040, adapted from (Odden et al., 2011).    
 
The costs associated with CVD on the national-level are both direct and indirect.  
Between 2010 and 2030, direct medical costs alone are expected to rise from $273 billion 
to $818 billion, while indirect costs associated with lost productivity are projected to rise 
from $172 billion to $276 billion, placing great strain on the nation’s healthcare system 
(Figure 3) (Heidenreich et al., 2011).   
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Figure 3.  Projected direct and indirect medical costs associated with CVD from 
2010 to 2030, adapted from (Heidenreich et al., 2011).    
 
Prevention is key in lessening the financial impact of the aging population.  
Population-based prevention interventions, as opposed to drug therapy or clinical 
interventions, are the most cost-effective way to prevent CHD.  Simple changes such as 
diet modification, physical activity, avoiding smoking, and controlling weight are all 
inexpensive ways to improve cardiovascular health and begin to minimize the 
consequences of heart disease on the nation’s healthcare system (Prosser et al., 2000).  
While the effects of CVD can be damaging on the individual and national levels, many of 
the risk factors associated with CHD are preventable through lifestyle changes, in 
particular diet modification. 
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Risk Factors for Cardiovascular Disease  
Introduction 
   Risk factors for CVD may be non-modifiable (including genetics, age, and sex) 
or modifiable (including diet, physical activity level, lipid status, BMI, blood pressure, 
and smoking/alcohol use) (Hsu et al., 2013).  Coronary heart disease kills nearly 380,000 
people in the US annually and even more are at risk of developing CHD as a result of 
modifiable lifestyle factors (Center for Disease Control and Prevention, 2014).  
Modifiable factors are related to more than 90% of the risk for a first heart attack (Hsu et 
al., 2013).  Two of the most common CVD risk factors, obesity and abnormal lipid status, 
are described below.   
Obesity 
 A BMI of 30 kg/m2 or greater indicates obesity and a BMI of 25-29.9 kg/m2 
indicates overweight (Table 1) (World Health Organization, 2000).   
Table 1.  Weight classification and BMI range for adults adapted from (WHO, 2000). 
 
Weight Classification BMI (kg/m
2
) 
Underweight < 18.50 
Normal 18.50 - 24.99 
Overweight ! 25 
Obese ! 30 
 
Obesity has reached epidemic proportions in the United States.  In 2011-2012, 16.9% of 
youth and 34.9% of adults were obese (Ogden et al., 2014).  Additionally, 68.5% of all 
adults aged 20 or older and 31.8% of youth ages 2 to 19 years old were overweight or 
obese (Ogden et al., 2014).  Overweight and obesity have significant consequences on 
health including positive associations with CHD and stroke as well as other CVD risk 
factors such as dyslipidemia, physical inactivity, type two diabetes mellitus (T2DM), and 
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hypertension, all of which are associated with atherosclerosis (U.S. Department of Health 
and Human Services, 2002).  While obesity impacts multiple risk factors for CVD, it has 
been increasingly recognized as an independent risk factor for CHD in the past decade 
(Nelms, Sucher, Lacey & Roth, 2011).  Additionally, although it is difficult to obtain the 
exact number of deaths due to obesity alone, it is estimated that obesity causes 300,000 
deaths per year in the United States (Flegal, Williamson, Pamuk, Rosenberg, 2004).   
It is important that obesity in the population is reduced to help lessen its impact 
on CHD incidence.  One study found that a 10% reduction in BMI over the next 30 years 
could help counteract the estimated increase in CHD incidence in the aging population by 
80% through blood pressure, cholesterol, and diabetes control (Odden et al., 2011).  
However, if the average BMI of adults increases by 10%, the incident cases of CHD are 
projected to more than double by 2040 (Odden et al., 2011). 
Cholesterol 
 Cholesterol is a precursor for many major hormones in the body, and is an 
important constituent of cell membranes and structures.  In the blood, cholesterol travels 
via lipoproteins, the major classes of which are low-density lipoprotein cholesterol (LDL-
C), high-density lipoprotein cholesterol (HDL-C), and very-low-density lipoprotein 
cholesterol (VLDL-C) (USDHHS, 2002).   
 Desirable total cholesterol (TC) levels are less than 200 mg/dL, whereas 
cholesterol levels of 200 to 239 mg/dL convey borderline-high risk for CVD, and levels 
of 240 mg/dL and above convey very high risk for CVD (Table 2) (American Heart 
Association, 2010).   
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Table 2.  Total cholesterol (TC) levels and classifications adapted from (AHA, 2010). 
 
Classification TC Level (mg/dL) 
Desirable Less than 200 
Borderline High 200-239 
High 240 and above 
 
Among adults in the United States, the average TC level is around 200 mg/dL, 
which is classified as borderline high risk for CVD (Roger et al., 2012).  Currently, 
13.8% of American adults have TC levels greater than or equal to 240 mg/dL and 
approximately 5.6% of adults have undiagnosed hypercholesterolemia (Fryar, Kirsch, 
Eberhardt, Yoon, & Wright, 2010).   
The effect of serum cholesterol on CVD risk is well documented.  Individuals 
with high TC are at double the risk of developing CVD compared to those with optimal 
levels (CDCP, 2014), and research shows that adults with higher cholesterol levels suffer 
more effects from atherosclerosis and CHD than those with lower levels (USDHHS, 
2002).  Early prevention is the key to reducing CVD risk associated with serum 
cholesterol levels.  One study found that when 42-year-old adults decrease their serum 
cholesterol by 10% they have a reduction in relative CHD risk of 50%, but if the same 
10% reduction in serum cholesterol is completed at age 70, the reduction in relative CHD 
risk is only 20% (Stamler et al., 2000).  Thus, early interventions to reduce TC levels may 
help decrease CVD risk later in life.   
Low-Density Lipoprotein Cholesterol (LDL-C) 
 The main function of LDL-C, which transports around 60% of total serum 
cholesterol, is to deliver cholesterol and other lipids to peripheral tissues (including the 
vascular epithelium) to be utilized for membrane construction or hormone synthesis 
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(Gropper, Smith, & Groff, 2009).  If LDL-C in the vascular epithelium becomes oxidized 
it can initiate the development of or add to existing atherosclerotic plaque, which is why 
LDL-C level is considered one of the best indicators of CVD risk and the main focus of 
cholesterol lowering therapy (USDHHS, 2002).  The largest component of LDL-C is 
cholesterol, while protein, triacylglycerols (TAG), and phospholipids compose the 
remaining sections.  Desirable levels of LDL-C are less than 100 mg/dL (or less than 70 
mg/dL for those already at risk for CVD) (Marieb & Hoehn, 2013); near/above optimal 
levels are 100 to 129 mg/dL; borderline high levels are 130 to 159 mg/dL; levels of 160 
to 189 mg/dL convey high risk of CVD; and levels of 190 mg/dL and above convey very 
high risk of CVD (Table 3) (AHA, 2010).   
Table 3.  Low-density lipoprotein cholesterol (LDL-C) levels and classifications 
adapted from (AHA, 2010). 
 
Classification LDL-C Level (mg/dL) 
Desirable Less than 100 
Near optimal/above optimal 100-129 
Borderline high 130-159 
High 160-189 
Very high 190 and above 
 
In 2007 to 2010 the average value of LDL-C among adults in the United States 
was 115.8 mg/dL, and in 1999 to 2004 the age-adjusted prevalence of high LDL-C 
among adults was 25.3% (Hyre, Muntner, Menke, Raggi, & He, 2007).  This rate is 
particularly troubling since LDL-C levels above 100 mg/dL seem to be atherogenic 
(Lloyd-Jones, Larson, Beiser, & Levy, 1999).  According to the Third Report of the 
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults, atherogenesis is significant in those with 
borderline high levels of LDL-C and is “markedly accelerated” among those with high 
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and very high LDL-C levels (USDHHS, 2002).  Thus, maintaining optimal LDL-C levels 
is essential to prevent atherosclerosis and maintain cardiovascular health. 
High-Density Lipoprotein Cholesterol (HDL-C) 
 The role of HDL-C in the blood stream is to scavenge unesterified cholesterol 
from areas where it has accumulated, including peripheral tissues, cells, and other 
lipoproteins, and deliver it to the liver for excretion.  High-density lipoprotein cholesterol 
can also compete with LDL-C for receptor sites in areas such as the vascular epithelium 
thereby reducing the risk of atherosclerosis (Gropper et al., 2009).  Unlike LDL-C, HDL-
C is composed primarily of protein with smaller amounts of cholesterol, phospholipids, 
and TAG, and comprises approximately 20% to 30% of serum cholesterol (Marieb & 
Hoehn, 2013).   
High-density lipoprotein cholesterol values of 60 mg/dL or higher provide 
protection against heart disease, while values of less than 40 mg/dL for men and less than 
50 mg/dL for women put the individual at greater risk of CVD (Table 4) (AHA, 2010).   
Table 4.  High-density lipoprotein cholesterol (HDL-C) levels and classifications 
adapted from (AHA, 2010). 
 
Classification HDL-C Level (mg/dL) 
Heart disease risk factor Less than 40 for men 
Less than 50 for women 
Protection against heart disease 60 or higher 
 
As of 2010, 21.8% of adults aged 20 years and older had HDL-C levels below 40 mg/dL 
(Go et al., 2014).  There is strong evidence to suggest that low levels of HDL-C are 
associated with CHD morbidity and mortality.  Studies have shown that HDL-C is an 
independent risk factor for CHD and that CHD risk increases between 2% and 3% for 
every 1% decrease in HDL-C (Gordon et al., 1989). 
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Triacylglycerols (TAG) 
 Triacylglycerols are composed of a glycerol backbone and three fatty acids, which 
may be saturated, unsaturated, polyunsaturated, or a combination (Gropper et al., 2009).  
They represent the most abundant and efficient storage form of fat in the body, producing 
large quantities of energy when oxidized (Marieb & Hoehn, 2013).  In addition, 95% of 
dietary fat comes from TAG, which varies in form depending on the composition of fatty 
acids (Gropper et al., 2009).   
A desirable blood TAG value is less than 150 mg/dL; 150 to 199 mg/dL is 
considered borderline-high risk; 200 to 499 mg/dL is considered high risk; and 500 
mg/dL or above is considered very high risk (Table 5) (AHA, 2010).   
Table 5.  Triacylglycerol (TAG) levels and classifications adapted from (AHA, 2010). 
 
Classification TAG Level (mg/dL) 
Desirable Less than 150 
Borderline-high  150-199 
High  200-499 
Very high 500 or higher 
 
Presently, 31% of adults in the United States have TAG levels greater than or 
equal to 150 mg/dL.  While TAG values have not been clearly identified as an 
independent risk factor for CVD, many studies have shown positive relationships 
between serum TAG levels and CHD incidence, and strong associations between high 
TAG values and CVD risk when combined with high LDL-C and low HDL-C as part of 
the atherogenic dyslipidemic triad (Miller et al., 2011).  Additionally, TAG values are 
associated with other known risk factors for CVD including obesity, hypertension, 
diabetes, and cigarette smoking (Grundy, 1998).   
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Obesity, TC, HDL-C, LDL-C, and TAG are all modifiable risk factors for CVD 
and are all strongly impacted by diet. 
 
Dietary Factors 
Dietary Patterns  
 Presently, neither children nor adults in the United States are consuming ideal 
diets.  Data from the National Health and Nutrition Examination Survey (NHANES) 
from 2009-2010 show that among children and teenagers, consumption of whole grain, 
fruits, and vegetables are far below national guidelines.  Fewer than 3% of children 
consume adequate amounts of vegetables per day and only between 5% and 10% of 
children consume enough fruit per day with consumption decreasing consistently with 
age (Go et al., 2014).  Similarly, fewer than 7% of all children meet guidelines for 
servings of whole grain per day, with an average of less than one serving per day in all 
age and sex groups (Go et al., 2014).  Children also consume high amounts of sugar-
sweetened beverages, sweets and bakery desserts, and processed meats.  For example, 
consumption of sugar-sweetened beverages increased with age from 7 to 8 servings per 
week in 5 to 9 year-olds to 13 to 16 servings per week in 15 to 19 year-olds (Go et al., 
2014).  Results are similar for adults (Krebs-Smith, Guenther, Subar, Kirkpatrick, & 
Dodd, 2010).   
Among adults aged 19 and older, 85.1% have usual fruit intakes below 
recommended amounts according to MyPyramid food groups, 86.8% do not consume 
adequate vegetables, and 98.8% do not consume enough whole grains (Krebs-Smith et 
al., 2010).  When compared to maximum discretionary calorie allowances, intakes of 
energy from solid fats, added sugars, and alcoholic beverages were over-consumed in 
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more than 90% of adults less than 72 years of age (Krebs-Smith et al., 2010).  While 
between only 31-47% of Americans are categorized as “ideal” by the American Heart 
Association’s Goals for 2020 in metrics of cardiovascular health such as physical 
activity, cholesterol levels, and BMI, a smaller fraction (0.5%) of Americans are 
categorized as “ideal” with regard to their healthy diet score (Figure 4) (Go et al., 2014).  
Part of this problem stems from the obesogenic environment in the United States today 
(Chaput, Klingenberg, Astrup, & Sjodin, 2011). 
 
 
Figure 4.  Prevalence estimates for poor, intermediate, and ideal cardiovascular 
health in US Adults !20 years based on four metrics of cardiovascular health from 
the American Heart Association 2020 goals, adapted from (Go et al., 2014). 
 
 In contrast to much of human history, where people spent extensive amounts of 
time and energy in search of food, food is now abundant, reasonably priced, and energy-
dense.  Fast-food options are increasingly available, meaning that more food is eaten 
outside of the home and often in large portions (Chaput et al., 2011).  These factors 
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contribute to the choices of many Americans to consume diets that are high in saturated 
fat, sodium, and added sugar in addition to being low in fiber (Hill, Wyatt, Reed, & 
Peters, 2003). 
This Western diet pattern is high in red meat, processed meat, refined grains, fried 
foods, sweets, and desserts (Heidemann et al., 2008), and has led to an overall increase in 
energy intake over time.  Data from NHANES comparing surveys from 1971 to 1974 and 
2005 to 2006 found that energy intake of females in the United States has increased by 
22% (from 1,542 to 1,886 kcal/day) and energy intake of males has increased 10% (from 
2,450 to 2,693 kcal/day) (Figure 5) (Nielsen & Popkin, 2003).  Additionally, between 
1970 and 2008 the net average daily per capita caloric intake increased by around 600 
kcals (U.S. Department of Agriculture and U.S. Department of Health and Human 
Services, 2010).   
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Figure 5.  Average daily energy intake of adult females and males in the United 
States from 1971-1974 and 2005-2006 NHANES data, adapted from (Nielsen & 
Popkin, 2003). 
 
The Western diet pattern negatively impacts CVD risk.  The INTERHEART 
study of 52 countries and more than 16,000 participants between 1999 and 2003 found 
that the risk of MI is 30% higher among those who consume a Western diet compared to 
those who consume a prudent diet (Iqbal et al., 2008).  A prudent diet is characterized by 
a high intake of fruit, vegetables, and legumes as well as lean protein sources such as fish 
and poultry (Iqbal et al., 2008).  Additionally, an 8-year prospective study of 44,875 men 
aged 40 to 75 years without diagnosed CVD showed that the Western diet pattern was 
associated with a 43% greater chance of CHD incidence in participants with the highest 
quintile of Western diet score compared to the lowest quintile of Western diet score 
(p=0.004).  The same study found that the prudent diet pattern was inversely associated 
with total CHD regardless of smoking status, body weight, or parental history of MI, with 
a 25% reduced risk of CHD among participants with the highest quintile of prudent diet 
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score compared to the lowest quintile of prudent diet score (p=0.02) (Hu et al., 2000).  
These studies show that long-term dietary patterns can greatly impact CVD risk.   
The Western and prudent diet patterns may also affect measures of adiposity.  A 
review of the Nurses’ Health Study II by Schulze et al. (2006), which followed 51,670 
women from 1991 to 1999, found that women who maintained a low Western diet score 
gained significantly less weight compared to women who maintained a high Western diet 
score over time (4.90 kg versus 5.62 kg, respectively, p< 0.001).  Additionally, compared 
to women who decreased their prudent diet score, those who increased their prudent diet 
score over time experienced less overall weight gain (7.98 kg versus 3.75 kg, 
respectively, p <0.001) (Schulze et al., 2006).  These results indicate that the prudent diet 
pattern may decrease the risk of weight gain over time whereas the Western diet pattern 
may increase the risk of weight gain over time.    
Similarly, a cross-sectional study by Denova-Gutierrez et al. (2011) of 6,070 men 
and women aged 20 to 70 years from the Health Workers Cohort Study found that the 
percentage of participants who were overweight or obese in the highest quintile of 
Western diet score was nearly 11% higher compared to the lowest quintile Western diet 
score (66.0% versus 55.8%, respectively).  Body fat percentage was also significantly 
higher among participants with the highest quintile Western diet score compared to the 
lowest quintile Western diet score (32.4% versus 29.8%, respectively; p < 0.001), 
whereas body fat percentage was significantly lower in the highest quintile of the prudent 
diet score compared to the lowest quintile prudent diet score (30.4% versus 31.8%, 
respectively; p=0.002) (Denova-Gutierrez et al., 2011).  These studies indicate that the 
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Western diet pattern may be associated with a higher risk of overweight/obesity and a 
high body fat percentage compared to the prudent diet pattern.   
The Western and prudent diet patterns may also impact the risk of developing 
metabolic syndrome (MetS), defined as any of three of the following risk factors: waist 
circumference (WC) >102 cm in men and >88 cm in women; TAG !150 mg/dL; HDL-C 
<40 mg/dL in men and <50 mg/dL in women; systolic blood pressure !130 mm Hg, 
diastolic blood pressure !85 mm Hg, or current use of antihypertensive medication; and 
fasting glucose !100 mg/dL or current drug treatment for elevated glucose (Grundy et al., 
2005).  The 9-year Atherosclerosis Risk in Communities Study, which followed 15,972 
men and women ages 45 to 64 years, found that the Western diet pattern was associated 
with an 18% greater risk of MetS incidence for participants in the highest quintile of 
Western diet scores compared to those in the lowest quintile of Western diet scores 
(Lutsey, Steffen, & Stevens, 2008).  As such, in comparison to the prudent diet pattern, 
the Western diet pattern may negatively impact multiple risk factors for CVD including 
measures of adiposity and blood lipids. 
Similar to the prudent diet pattern, the Mediterranean diet (which includes a high 
intake of olive oil, fruit, nuts, vegetables, and cereals; modest fish and poultry intake; and 
only small amounts of dairy products, red and processed meats, and sweets) has been 
associated with beneficial effects on cardiovascular health.  A dietary intervention study 
comparing the Mediterranean diet to a control diet in 7,447 subjects at high 
cardiovascular risk found that the Mediterranean diet reduced the incidence of major 
cardiovascular events by nearly 30% (Estruch et al., 2013).  Additionally, Fung et al. 
(2009) reviewed data from 74,886 women ages 38 to 63 in the Nurses’ Health Study and 
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found that those with the highest quintile Alternate Mediterranean Diet (aMed) Score 
(which encompassed high consumption of plant foods, plant protein, monounsaturated 
fat, and fish; and low consumption of animal products and saturated fat) had a 29% lower 
risk of developing CHD compared to the lowest quintile aMed score.  Therefore, the 
Mediterranean diet pattern may be associated with a lower risk of CHD as well as 
cardiovascular events.   
The Mediterranean diet has also been associated with changes in measures of 
adiposity.  A cross-sectional study of 1,547 men and 1,615 women aged 25 to 74 in 
northeast Spain found that increased adherence to the Mediterranean diet was associated 
with reductions in WC of 0.43 inches men (p=0.030) and 0.68 inches women (p=0.007), 
as well as a 39% reduced risk of obesity among both sexes when comparing the highest 
to lowest tertile Mediterranean diet scores (Schroder, Marrugat, Vila, Covas, & Elosua, 
2004).  Additionally, a 3-year prospective study following 17,238 non-obese women and 
10,589 non-obese men from the Spanish cohort of the European Prospective Investigation 
into Cancer and Nutrition found that high adherence to the Mediterranean diet was 
associated with a 31% reduction in obesity incidence in both women and men (Mendez et 
al., 2006).  This suggests that the Mediterranean diet pattern may be beneficial in helping 
to reduce the risk of obesity in both men and women. 
The Mediterranean diet may also affect the lipid profile.  In a 3-month dietary 
intervention among 212 male and female volunteers, participants in the Mediterranean 
diet group showed a significant decrease in TC (6.6 ± 1.0 to 6.2 ± 1.0 mmol/L, p<0.001) 
and TAG (1.6 ± 1.0 to 1.4 ± 0.9 mmol/L, p<0.001) (Vincent-Baudry et al., 2005).  In 
addition, a 4-week randomized crossover study (where 22 healthy subjects were fed a 
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Mediterranean diet or an ordinary Swedish diet) found that compared to the Swedish diet, 
the Mediterranean diet decreased TC, LDL-C, and TAG by 17%, 22%, and 17%, 
respectively (Ambring et al., 2004).  Similar to the prudent diet pattern (and in contrast to 
the Western diet pattern), the Mediterranean diet pattern is associated with a reduced risk 
of CVD, overweight/obesity, and abnormal blood lipids.   
 Plant-based diets have also been associated with favorable impacts on CVD risk.  
This dietary pattern emphasizes consumption of a variety of plant foods including fruits, 
vegetables, nuts, seeds, legumes, and cereal grains (Pilis, Stec, Zych, & Pilis, 2014), and 
limits animal products and highly processed foods (Tuso et al., 2013).  It has been shown 
to be high in phytochemicals, fiber, antioxidants, magnesium, vitamins C and E, and folic 
acid while low in cholesterol, total fat, saturated fatty acids (SFA), and sodium (Li, 
2013).  This nutrient profile is associated with reduced risk of atherosclerosis, CHD, 
T2DM, obesity, cancer, and MetS (Pilis et al., 2014) due to beneficial effects on BMI, 
cholesterol levels, and blood pressure (McEvoy, Temple, & Woodside, 2012).   
A meta-analysis by Li (2013) of 124,706 participants from seven prospective 
cohort studies determined that compared with omnivores, vegetarians had 29% lower 
mortality from CHD, 16% lower mortality from circulatory diseases, and 12% lower 
mortality from cerebrovascular diseases.  Lower mortality rates among vegetarians were 
associated with improvements in TC, TAG, and LDL-C; improvements in ratios of 
TC/HDL-C, LDL-C/HDL-C, and TAG/HDL-C; decreased blood pressure; and lower 
BMI and waist-to-hip ratio (Li, 2013).  According to Sabaté and Wien (2010), a meta-
analysis of studies on adult vegetarians showed that vegetarians had 2 kg/m2 lower BMI 
values than non-vegetarians.  The same study found that male and female vegetarians 
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weighed 7.6 kg and 3.3 kg less, respectively, than non-vegetarians of the same sex.  
These studies indicate that plant-based diets may help reduce the risk of mortality due to 
CVD by improving blood lipid status and measures of adiposity such as BMI. 
Plant-based diets may even be associated with reversing certain aspects of CVD 
progression.  The Lifestyle Heart Trial found that when patients with heart disease 
consumed a plant-based diet, 82% had some level of regression of atherosclerosis (Ornish 
et al., 1990).  Among the treatment group given a plant-based diet, participants showed a 
40% decrease in LDL-C at year one, which was maintained at 20% below baseline at 
year five.  Reductions of this magnitude are similar to those seen with lipid-lowering 
medications, indicating that lifestyle changes alone can impact cardiovascular health 
(Ornish et al., 1990; Ornish et al., 1998).   
Plant-based diets that include nuts have reported similar beneficial effects as a 
plant-based diet without nuts, but with a greater magnitude.  A review of small, 
randomized trials suggests that while vegetarian and lacto-ovo-vegetarian diets reduced 
TC and LDL-C by 10-15%, a vegetarian diet with added fiber, soya, and nuts reduced TC 
and LDL-C by 20-35% (Ferdowsian & Barnard, 2009).  While the prudent, 
Mediterranean, and plant-based diets are all associated with positive effects on CVD risk, 
lipid profile, and measures of adiposity, those that include nuts may be more beneficial 
compared to plant-based diets without nuts.  Therefore, the study of nuts in the diet is 
important to better understand their effects on cardiovascular health.   
Nuts  
Introduction 
 The term “nut” refers to tree nuts and peanuts (peanuts botanically are considered 
groundnuts or legumes but are widely accepted as nuts by the consumer definition), with 
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the most popular nuts being almonds, peanuts, walnuts, pecans, and pistachios (Ros, 
2010).  Nuts are recognized as a healthy dietary component in many countries (Vadivel, 
Kunyanga, & Biesalki, 2012) including the United States, Canada, and Spain, which have 
all included nuts into their recommended dietary guidelines (Chen & Blumberg, 2008).  
Since the year 2000 the AHA has recommended nuts as part of a healthy diet, and a 
recent report by the AHA stipulating goals for 2020 to reduce disease and promote health 
included nuts as an important component in the ideal diet for cardiovascular health 
(Lloyd-Jones et al., 2009).  Additionally, in the summer of 2003 the United States Food 
and Drug Administration (USFDA) issued a qualified health claim for the association of 
nut consumption and reduced risk of CHD reporting that, “Scientific evidence suggests 
but does not prove that eating 1.5 oz per day of most nuts, such as pistachios, as part of a 
diet low in saturated fat and cholesterol may reduce the risk of heart disease” (O’Neil, 
Keast, Fulgoni, & Nichlas, 2010).  This claim was supported by the 2010 Dietary 
Guidelines Advisory Committee, which stated that research most strongly supported this 
claim for almonds, pistachios, and walnuts (USDA and USDHHS, 2010).  Consequently, 
nuts have gained recognition as a healthy food option (Nash & Nash, 2008). 
Effects on Cardiovascular Health 
 Nuts have been shown to have beneficial health effects due to their 
cardioprotective, antidiabetic, antioxidant, anti-inflammatory, and hypocholesterolemic 
properties (Vadivel et al., 2012).  Results from epidemiologic studies have been 
consistent in establishing the protective effects of nuts on cardiovascular health.  A 
review of four large cohort studies (the Adventist Health Study, the Iowa Women’s 
Health Study, the Nurses’ Health Study, and the Physician’s Health Study) has shown 
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that nut consumption reduces the risk of CHD in a dose-dependent manner.  Results from 
these four studies indicated that the average reduction in risk of death from CHD was 
8.3% for each weekly serving of nuts, which equated to a 37% reduced risk of CHD 
death overall (Kelly Jr. & Sabaté, 2006).   
Furthermore, nuts have been associated with improved glycemic control and 
reduced fasting insulin levels (Josse, Kendall, Augustin, Ellis, & Jenkins, 2007) and have 
been found to help reduce the risk of developing T2DM (Jenkins, Hu, Tapsell, Josse, & 
Kendall, 2008).  The beneficial effects on treatment and prevention of T2DM may be due 
to the anti-inflammatory and antioxidant potential of nuts (Casas-Agustench et al., 2009).   
Nuts have antioxidant properties due to their distinct nutrient profile.  Nuts 
contain phenolic compounds and antioxidant vitamins, which have been shown to inhibit 
LDL-C oxidation (Blomhoff, Carlsen, Andersen, & Jacobs, 2006).  Additionally, nuts 
contain a relatively high amount of monounsaturated fatty acids (MUFA), which are not 
vulnerable to oxidation.  While nuts also contain polyunsaturated fatty acids (PUFA), 
which may be more easily oxidized, the other antioxidant components present in nuts 
help to counteract any oxidation that may occur (Alexiadou & Katsilambros, 2011).   
Nut consumption may also have beneficial impacts on inflammation.  The Multi-
Ethnic Study of Atherosclerosis composed of 6,000 men and women aged 45 to 84 years 
examined the relationship between nut consumption and inflammatory markers, and their 
relation to atherosclerosis.  Researchers found a significant inverse association between 
nut consumption and markers of inflammation including C-reactive protein, interleukin-
6, and fibrinogen (Sabaté & Ang, 2009).   
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Nut consumption has also been shown to beneficially impact flow-mediated 
dilation (a standard method to assess endothelial function) (Ros, 2010) and reduce 
endothelial dysfunction due to hypercholesterolemia.  Because endothelial dysfunction is 
associated with the progression of atherosclerosis, nut consumption may help prevent 
atherosclerosis and thus CVD (Ros et al., 2004).   
Effects on Measures of Adiposity 
 While nuts have a high energy density and fat content, evidence suggests that 
when consumed in moderation as part of a healthy diet their consumption does not 
increase the risk of becoming overweight or obese (Flores-Mateo, Rojas-Rueda, Basora, 
Ros, & Salas-Salvadó, 2013).  For example, Mediterranean populations consume nearly 
double the amount of nuts per capita than Americans but have much lower rates of 
obesity (Sabaté, 1993).  Additionally, multiple large prospective cohort studies and 
controlled feeding trials have found an inverse relationship between frequency of nut 
consumption and BMI (Flores-Mateo et al., 2013).  The Seguimiento Universidad de 
Navarra study (composed of 8,865 adults in a Mediterranean population) showed that 
even after adjusting for baseline BMI, participants who consumed nuts more than twice 
per week had a 40% lower risk of weight gain and a 43% reduced risk of becoming 
overweight/obese compared to those who never or rarely consumed nuts (Bes-Rastrollo 
et al., 2007).  Frequent nut consumers may weigh less and have less chance of gaining 
weight than their counterparts who consume nuts infrequently (Fraser, Sabaté, Beeson, & 
Strahan, 1992).   
A review of nut-feeding studies by Sabaté (2003) found that nuts consistently 
were not associated with weight gain when consumed during short-term trials in 
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moderate to large quantities.  Well-controlled feeding studies, controlled crossover 
feeding studies, and other intervention studies have shown no significant association 
between nut consumption and weight change.  This evidence suggests that when nuts are 
substituted into the diet they are not associated with significant changes in weight. 
Effects on Blood Lipids 
 Clinical trials have consistently shown the hypocholesterolemic effects of nut 
consumption.  A review by Sabaté, Oda, and Ros (2010) of 25 clinical trials evaluating 
the effects of nut consumption on the lipid profile consisted of 1,284 observations from 
583 participants in 7 different countries.  While the type of nuts consumed and the range 
of dietary control varied greatly among the studies, results showed consistent cholesterol-
lowering effects among all age groups and genders, independent of the type of nut 
consumed.  The average estimated reduction of TC was 11 mg/dL (5%) and of LDL-C 
was 10 mg/dL (7%) in response to an average daily intake of 67 g of nuts or 
approximately 20% of energy.  Reductions in both TC and LDL-C occurred in a dose-
dependent manner.  Among patients with high serum TAG values (greater than 150 
mg/dL) a significant reduction of 10.2 mg/dL was also observed (Sabaté et al., 2010).   
This review also found that the decrease in LDL-C was greater than predicted 
based on the differences in fatty acid and cholesterol composition between nut and 
control diets.  The authors suggest that the enhanced cholesterol-reducing effects of nuts 
can be attributed to other nutritional components such as fiber and phytosterols (Sabaté et 
al., 2010).  Previous research has indicated that the lipids from nuts may not be efficiently 
absorbed (Baer et al., 2012).  Because plant cell walls control the degree and speed with 
which lipids are released during digestion, whole nuts have been shown to cause smaller 
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increases in postprandial lipemia when compared to their respective oils or flours.  Berry 
et al. (2008) found that following the consumption of almond seeds, increases in TAG 
among participants were lower compared to increases in TAG following consumption of 
almond oil or flour.  Additionally, an intervention trial of 63 healthy men and women 
found that consumption of whole peanuts equated to greater fecal fat and energy loss 
when compared to peanut butter, oil, or flour.  The fact that the energy in nuts is not fully 
absorbed during digestion is one reason why nuts may be considered as part of a healthy 
diet without excessive concern for weight gain or negative impacts on the lipid profile 
(Traoret et al., 2008).   
Compared to the top three most highly consumed nuts in the US, as reviewed in 
the studies above, pistachios have fewer calories and less total fat per serving, giving 
them the potential to induce similar cardiovascular benefits with reduced energy and fat 
intake.  The following section will highlight the nutrient composition of pistachios and 
the subsequent impacts of pistachio consumption on measures of adiposity and the lipid 
profile.   
 
Pistachios 
Introduction  
 The pistachio (Pistacia vera L.) is a tree nut in the family Anacardiaceae (Herber 
& Bowerman, 2008).  While researchers have only recently begun studying the various 
health benefits of pistachios, different populations have been taking advantage of their 
healthful properties for centuries.  For millennia pistachios have been utilized for their 
nutritional properties and have been used to treat diseases.  Pistachios were even used in 
ancient Greek and Assyrian civilizations to remedy bites from poisonous animals and as 
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folk remedies for numerous conditions.  They were a valuable food for early explorers 
and traders due to their high nutritional value and relatively light weight (Salas-Salvadó, 
Casas-Agustench, & Salas-Huetos, 2011).  The largest producers of pistachios worldwide 
are California and Iran, each producing hundreds of millions of pounds annually (Dreher, 
2012).   
Biochemical Composition  
 The unique biochemical composition of pistachios yields beneficial effects on 
cardiovascular health by impacting lipid status, glycemic control, blood pressure, and 
measures of adiposity (Kris-Etherton et al., 2008).  Pistachios are rich in unsaturated fatty 
acids, phytosterols, lutein, dietary fiber, protein, magnesium, carotenoids, gamma-
tocopherol, phenolic compounds, and potassium (U.S. Department of Agriculture, 2015).  
In comparison to other tree nuts, pistachios contain higher levels of phytosterols, 
potassium, carotenoids, and tocopherols (Phillips, Ruggio, & Ashraf-Khorassani, 2005).  
Compared to almonds, peanuts, pecans, and walnuts, pistachios have fewer calories and 
less fat per serving (USDA, 2015) (Table 6).   
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Table 6.  Average nutrient composition of selected nuts per 100g
1
 adapted from (USDA, 2015). 
 
Nuts Energy 
(kcal) 
Total 
Fat 
(g) 
SFA 
(g) 
MUFA 
(g) 
PUFA 
(g) 
Total 
Protein 
(g) 
Plant 
Sterols 
(mg) 
Fiber 
(g) 
Ca 
(mg) 
Mg 
(mg) 
K 
(mg) 
Lutein and 
zeaxanthin 
(!g) 
Beta-
carotene 
(!g) 
Gamma-
tocopherol 
(mg) 
Pistachios 562 45.39 5.556 23.82 13.74 20.27 214 10.3 105 121 1025 1405 249 22.6 
Almonds 579 49.93 3.802 31.55 12.33 21.15 120 12.5 269 270 733 1 1 0.64 
Peanuts 567 49.24 6.279 24.43 15.56 25.8 NR 8.5 92 168 705 0 0 NR 
Pecans 691 71.97 6.180 40.80 21.61 9.17 102 9.6 70 121 410 NR NR NR 
Walnuts 654 65.21 6.126 8.933 47.17 15.23 72 6.7 98 158 441 9 12 20.83 
1
Data are from raw nuts.  SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; Ca, 
calcium; Mg, magnesium; K, potassium; NR, not reported.  
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The nutrients found in pistachios that are likely to have the greatest impact on 
improving lipid status are unsaturated fatty acids, phytosterols, dietary fiber, protein, and 
magnesium (Dreher, 2012).  Studies have shown that the pistachio’s high unsaturated fat 
percentage relative to saturated fat content is the most influential factor affecting lipid 
status (Berglund et al., 2007).  One hundred grams of pistachios contains 45.39 g of total 
fat including 5.56 g of SFA, 13.74 g of PUFA, and 23.82 g of MUFA (USDA, 2015).  
The phytosterol content of pistachios (which is 214 mg per 100 g and the highest among 
all tree nuts) is also beneficial to the lipid profile (Phillips et al., 2005).  The structure of 
phytosterols resembles that of cholesterol, which can impede cholesterol absorption 
(Ostlund, 2007).  The insoluble fiber found in pistachios (which accounts for 80% of the 
fiber in pistachios) has also been shown to cause both cholesterol and bile to be less 
efficiently absorbed by increasing fecal bulk and decreasing intestinal transit time (Salas-
Salvadó, Bulló, Pérez-Heras, & Ros, 2006).  Low-density lipoprotein cholesterol levels, 
in particular, may be improved with the consumption of plant-based protein when 
consumed in place of carbohydrates (pistachios contain 20.27 g of plant-based protein per 
100g) (USDA, 2015; Wolfe & Giovannetti, 1991).  Pistachios also contain magnesium, 
which has been linked to improvements in hyperlipidemia (Kishimoto et al., 2010).    
 Pistachios have been listed among the top fifty foods highest in antioxidants 
(Halvorsen et al., 2006) and contain an abundance of both water- and fat-soluble 
antioxidants including carotenoids, gamma-tocopherol, and phenolic compounds.  
Reduced antioxidant values can lead to oxidative stress which impacts CHD progression 
(Kay et al., 2010), and oxidized LDL-C has been implicated in the initiation and 
progression of atherosclerotic plaques, which may lead to CVD (Toshima et al., 2000).  
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Conversely, the consumption of antioxidants, like those found in pistachios, has been 
linked to protection against early atherosclerosis, decreases in oxidized LDL-C, and an 
inverse association with CHD (Dreher, 2012).   
Pistachios have also been associated with improvements in fasting blood glucose 
and insulin levels (Sari et al., 2010), and hemodynamics (Sauder, McCrea, Ulbrecht, 
Kris-Etherton, & West, 2014).  Improved fasting blood glucose and insulin levels may 
help reduce the risk of T2DM (a risk factor for CVD) (Kendall, Josse, Esfahani, & 
Jenkins, 2011), and the beneficial effects of pistachios on multiple hemodynamic 
measures such as stroke volume, cardiac output, and total peripheral resistance may be 
associated with a reduced risk of CVD outcomes (Sauder et al., 2014).   
Effects on Measures of Adiposity  
Nine studies have investigated the effects of a pistachio-supplemented diet on 
body weight, WC, intra-abdominal adipose tissue (IAAT), subcutaneous abdominal tissue 
(SCAT), waist-to-hip ratio, and BMI (Aldemir et al., 2011; Edwards et al., 1999; Gebauer 
et al., 2008; Gulati et al., 2014; Li et al., 2010; Sari et al., 2010; Kocygit et al., 2006; 
Sheridan et al., 2007) (Table 7).   
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Table 7.  Published clinical trials on effects of pistachio consumption on measures of adiposity and blood lipids. 
 
Study Characteristics of subjects Number and 
age of 
subjects 
Study type Intervention Duration Outcome 
measure 
Study results 
Sheridan, 
Cooper, 
Erario, & 
Cheifetz, 
2007 
Primary, moderate 
hypercholesterolemia  
 
Mean TC 246 ± 6 mg/dL 
 
Mean BMI 28 ± 0.9 kg/m
2
 
15; 11 men 
and 4 women, 
average age 
60 ± 3 years 
(range 36 to 
75 years) 
Randomized 
crossover 
trial w/ 
dietary 
counseling 
15% daily caloric 
intake from 
pistachios 
substituted for fat 
calories or high 
fat snacks 
4 weeks Blood lipids 
BMI 
Decreased TC/HDL-C (p<0.001), LDL-
C/HDL-C (p=0.004) between diets 
Increased HDL-C (p=0.02) between diets 
Decrease in LDL-C (p=0.04) and LDL-
C/HDL-C (p=0.009) from baseline  
Nonsignificant reductions for TC, TAG, 
LDL-C between diets 
Nonsignificant changes in BMI between or 
within diets 
Kocygit, 
Koylu, & 
Keles, 2006 
Healthy men and women  
 
Mean TC 159 mg/dL 
 
Mean body weight 64 kg 
(range 55-87 kg) 
44; control 
group, n=22, 
33 ± 6.7 
years; 
pistachio 
group, n=22, 
33 ± 7.2 years 
Randomized 
control trial 
w/ dietary 
counseling 
20% daily caloric 
intake from 
pistachios (65-75 
g/day) substituted 
for fatty foods and 
visible fats 
3 weeks Blood lipids 
BMI 
Decreased TC (p<0.05), TC/HDL-C 
(p<0.001), LDL-C/HDL-C (p<0.005) 
Increased HDL-C (p<0.001) 
Nonsignificant decreases in LDL-C and 
TAG 
Nonsignificant change in BMI 
Edwards, 
Kwaw, 
Matud, & 
Kurtz, 1999 
Primary, moderate 
hypercholesterolemia  
 
Median TC 243 mg/dL 
(range 214-336 mg/dL) 
 
Median weight 64 kg (range 
55-102 kg) 
10; 4 men 
(range 41 to 
53 years) and 
6 women 
(range 28 to 
64 years) 
Randomized 
crossover 
trial w/ 
dietary 
counseling 
20% daily caloric 
intake from 
pistachios 
substituted for fat 
calories or high 
fat snacks  
3 weeks Blood lipids 
Body weight 
Decreased TC (p<0.04), TC/HDL-C 
(p<0.01), LDL-C/HDL-C (p<0.02) 
Increased HDL-C (p<0.09) 
Nonsignificant decreases in TAG and LDL-
C 
Nonsignificant change in body weight 
Gebauer, 
West, Kay, 
Alaupovic, 
Bagshaw, 
& Kris-
Etherton, 
2008 
Elevated LDL-C  
 
Mean LDL-C 137 mg/dL 
(range 90-191 mg/dL) 
 
Mean BMI 26.8 ± 0.7 kg/m
2
 
28; 10 men 
and 18 
women, 
average age 
48 ± 1.5 years 
Randomized 
crossover 
controlled 
feeding trial  
3 isoenergetic 
diets: 
Control diet – 
Step I diet with no 
pistachios 
 
Pistachios as 10% 
4 weeks Blood lipids  
Body weight 
Decreased TC and LDL-C with both the 
10% and 20% energy diets (p<0.001) 
Decreased TAG (p<0.01), TC/HDL-C 
(p<0.001), and LDL-C/HDL-C (p<0.001) 
with 20% energy diets  
Differences between 10% and 20% energy 
diets for TC/HDL-C and LDL-C/HDL-C 
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of total energy 
(range 32 to 63 
g/d) 
 
Pistachios as 20% 
of total energy 
(range 63 to 126 
g/d) 
(p<0.05) indicating a dose-dependent effect 
Nonsignificant differences in HDL-C or 
body weight  
Sari et al., 
2010 
Healthy young men  
 
Mean TC 200 ± 41.8 mg/dL 
 
Mean body weight 69.3 ± 
4.9 kg 
32; average 
age 22 years 
(range 21 to 
24 years) 
Randomized 
control trial 
Mediterranean-
type diet for 4 
weeks, then 20% 
daily caloric 
intake (60 to 
100g) from 
pistachios added 
to replace MUFA 
content for 
another 4 weeks 
 
4 weeks Blood lipids 
Body weight 
Decreased LDL-C (p<0.001), TC 
(p<0.001), TAG (p=0.008), TC/HDL-C 
(p<0.001), and LDL-C/HDL-C (p<0.001) 
Nonsignificant change in HDL-C (p=0.069) 
Nonsignificant changes in body weight 
Li et al., 
2010 
Overweight or obese adults 
 
Mean TC: 
 
Pistachio – 197 ± 5.6 mg/dL 
Pretzel – 205 ± 8.4 mg/dL 
 
Mean BMI range 27 to 35 
kg/m
2
 
52; (range 20 
to 65 years) 
Randomized 
control trial 
Meal plans of 
1200, 1400, or 
1600 kcal based 
on 500 kcal per 
day less than 
resting metabolic 
rate with 
isocaloric daily 
snack of either 
53g pistachios or 
56g pretzels 
12 weeks Blood lipids 
BMI 
Body weight 
Decreased TAG (p<0.05) at 6 and 12 weeks 
Decreased body weight in both groups from 
baseline (p<0.01) 
Decreased BMI in both groups from 
baseline (p<0.05) 
Decreased BMI in pistachio versus pretzel 
group every 2 weeks except for week 10 
(p=0.08) 
Nonsignificant changes in TC, LDL-C, and 
HDL-C 
Nonsignificant decrease in body weight in 
pistachio versus pretzel group (p=0.09) 
Baer, 
Gebauer, & 
Novotny, 
2012 
Healthy adults  
 
Mean LDL-C 115 mg/dL 
(range 80 to 183 mg/dL) 
 
Mean BMI 27.9 kg/m
2
 
16; 8 men 
and 8 women, 
average age 
50 years 
(range 29 to 
64 years) 
Randomized 
crossover 
controlled 
feeding trial 
3 isocaloric diets: 
0 g/day control 
diet 
42 g/day pistachio 
diet 
84 g/day pistachio 
3 weeks Blood lipids 
 
Decreased LDL-C after 42 g/day diet 
(p=0.04), no additional reduction after 84 
g/day diet 
Nonsignificant changes in TC, HDL-C, and 
TAG 
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(range 20.8 to 34.5 kg/m
2
) diet 
Aldemir, 
Okulu, 
Neselioglu, 
Erel, & 
Kayigil, 
2011 
Men with erectile 
dysfunction  
 
Mean TC 179.5 ± 53.2 
mg/dL 
 
Mean BMI 27.33 ± 2.88 
kg/m
2
 
17; average 
age 47.9 ± 
6.2 years 
(range 38-59 
years) 
Prospective 
study 
20% daily caloric 
intake from 
pistachios (100g 
or 570 kcal) every 
day at lunch  
3 weeks Blood lipids 
BMI 
Decreased TC (p=0.008), LDL-C 
(p=0.007), TC/HDL-C (p=0.001), LDL-
C/HDL-C (p=0.001), and TAG/HDL-C 
(p=0.013) 
Increased HDL-C (p=0.001) 
Nonsignificant decrease in TAG (p=0.288) 
Nonsignificant changes in BMI 
Gulati, 
Misra, 
Randey, 
Bhatt, & 
Saluja, 
2013 
Asian Indians with MetS  
 
Mean TC 192.5 ± 35.1 
mg/dL 
 
Mean body weight 80.9 ± 
11.6 kg  
 
Mean BMI 30.9 ± 75 kg/m
2
 
 
Mean WC 104.86 ± 8.4 cm 
68; 37 men 
and 31 
women, 
average age 
42.5 ± 8.2 
years 
Randomized 
controlled 
parallel 
study 
20% daily caloric 
intake from 
pistachios 
substituted for 
visible fat, a 
portion of 
carbohydrates, 
and dairy 
24 weeks Blood lipids 
Body weight 
WC 
SCAT 
IAAT 
 
Decreased WC (p=0.02)  
Decreased TC (p=0.02) and LDL-C 
(p<0.006) 
Nonsignificant decrease in SCAT (p=0.07) 
Nonsignificant decrease in IAAT (p=0.7) 
Nonsignificant change in weight (p=0.7) 
Nonsignificant increase in HDL-C (p=0.9) 
Nonsignificant decrease in TAG (p=0.5) 
Wang, Li, 
Liu, Lv, & 
Yang, 2012 
Chinese subjects with MetS 
 
Mean TC: 
 
RSG – 204.6 ± 39.1 mg/dL 
HSG – 204.6 ± 36.0 mg/dL 
DCG – 193.7 ± 38.3 mg/dL  
 
Mean BMI: 
 
RSG – 28.12 ± 3.22 kg/m
2
 
HSG – 28.01 ± 4.51 kg/m
2 
DCG – 28.03 ± 4.35 kg/m
2
 
 
 
90; 41 men 
and 49 
women, 
average age: 
 
RSG – 51.89 
± 8.82 years 
HSG – 51.83 
± 9.37 years 
DCG – 50.66 
± 9.86 years 
Randomized 
control trial 
RSG – 42 g/day 
pistachios 
HSG – 70 g/day 
pistachios 
DCG – no 
pistachios 
 
All participants 
counseled on 
AHA Step 1 diet 
12 weeks Blood lipids 
Body weight 
BMI 
Waist-to-hip 
ratio 
Decreased TAG in 42 g/day group 
(p=0.018) 
Increased LDL-C in 70 g/day group 
(p=0.003) and the control group (p=0.037) 
Nonsignificant change in LDL-C in 42 
g/day group  
Nonsignificant decrease in TAG in 70 g/day 
group 
Nonsignificant changes in TC in any diet 
group 
Nonsignificant changes in HDL-C in any 
diet group 
Nonsignificant changes in body weight 
Nonsignificant changes in BMI 
Nonsignificant changes in waist-to-hip ratio 
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The amount of pistachios consumed in these studies ranged from 42 g to 100 g, or 
10% to 20% of energy intake.  Researchers found that none of the measures of adiposity 
increased significantly following a diet supplemented with pistachios, and two studies 
showed significant reductions among these variables (Gulati et al., 2014; Li et al., 2010).   
The randomized control trial by Gulati et al. (2014) involved the longest 
intervention period of any previous experiment with pistachios.  In a 24-week free-living 
randomized control trial, 60 Asian Indians with MetS were designated to consume either 
a control diet based on dietary guidelines for Asian Indians containing 60% 
carbohydrates, 15% protein, and 25% fat or a diet supplemented with pistachios as 20% 
of total energy making the ratio of carbohydrates, protein, and fat 51%, 20%, and 29%, 
respectively.  Both groups were advised to consume a diet rich in vegetables and fruits; 
whole-grain, high-fiber foods; choose white meats over red meats; choose low-fat or fat-
free dairy products; and limit consumption of hydrogenated oils, soft drinks, food with 
added sugar, salty foods and alcohol.  The pistachio group was educated on how to 
incorporate pistachios into their diet by replacing visible fat, some carbohydrates, and 
dairy.  Physical activity was to remain stable throughout the study. 
Results showed that there was no significant change in body weight or IAAT 
between groups at the end of the intervention.  However, WC decreased significantly in 
the intervention group versus the control group and there was a trend toward reduction in 
SCAT (Gulati et al., 2014).   
After the 24-week intervention, the average weight of the intervention group 
(adjusted for sex and baseline values) compared to the control group was 79.1 ± 2.1 kg 
versus 78.9 ± 2.1 kg, respectively, and the average IAAT was 107.1 ± 16.3 cm2 versus 
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114.3 ± 114.3 cm2, respectively.  The difference between intervention group and control 
group at a 95% confidence interval was -0.21 (-1.2 to 0.82) for weight in kg (p=0.7) and 
7.2 (-32.9 to 47.4) for IAAT in cm2 (p=0.7).  Additionally, the mean WC of the 
intervention group was 100.9 ± 2.6 cm versus 102.5 ± 2.6 cm in the control group, a 
difference of 1.5 (0.3 to 2.8) cm (p<0.03).  The mean SCAT for the intervention group 
was 168.7 ± 27.2 cm2 versus 180.4 ± 27.2 cm2 in the control group, a difference of 11.8 (-
1.4 to 24.9) cm2 (p<0.07) (Gulati et al., 2014).  This study showed that incorporating 
pistachios into a healthy diet was not associated with weight gain or increased central 
adiposity and may be associated with reduced WC and SCAT in Asian Indians with 
MetS.   
A second randomized control trial by Li et al. (2010) also showed significant 
reductions in measures of adiposity.  Fifty-nine overweight or obese free-living 
participants between the ages of 20 and 65 years with BMI between 27 and 35 kg/m2 
were randomly assigned to consume isocaloric weight reduction diets.  The diets 
consisted of 1200, 1400, or 1600 kcal, which equated to 500 kcals per day less than 
resting metabolic rate.  Roughly half of the participants consumed 53 g (240 kcal) of 
salted pistachios for a snack each day while the other half consumed 56 g (220 kcal) of 
salted pretzels each day.  Pistachios replaced carbohydrates in the pistachio group so the 
groups consumed diets that were isocaloric but had different macronutrient compositions 
(the pretzel group was approximately 20% fat, 15% protein, and 65% carbohydrate; and 
the pistachio group was approximately 30% fat, 15% protein, and 55% carbohydrate).  
Participants filled out food records and met with a dietitian every 2 weeks for compliance 
but made all of their own meals.   
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Participants in both groups lost a significant amount of weight compared to 
baseline after the 12-week study (reduced from 86.0 ± 1.4 to 82.3 ± 1.6 kg, p<0.01 in the 
pistachio group and from 85.5 ± 2.2 to 82.8 ± 2.5 kg, p<0.01 in the pretzel group).  There 
was a non-statistically significant trend for the pistachio group to lose more weight than 
the pretzel group (p=0.09).  At the end of 12 weeks, while both groups experienced 
significant reductions in BMI (30.1 ± 0.4 at baseline to 28.8 ± 0.4 kg/m2 in the pistachio 
group, p<0.05 versus 30.9 ± 0.4 to 30.3 ± 0.5 kg/m2 in the pretzel group, p<0.05), the 
pistachio group had a significantly greater reduction in BMI (4.3%) compared to the 
pretzel group (2%) except during week 10 when p=0.08 (Li et al., 2010).  When 
compared to a refined carbohydrate snack, an isocaloric quantity of pistachios as part of a 
weight reduction diet helped lower BMI in overweight or obese participants.   
A third randomized control trial by Wang et al. (2012) investigated the effects of 
pistachio consumption on measures of adiposity in Chinese participants with MetS.  
Participants, who ranged from 25 to 65 years old, were educated on how to follow the 
American Heart Association Step 1 diet (a diet low in fat and cholesterol designed to 
lower CVD risk) and told not to consume any tree nuts.  Participants were randomly 
assigned to either a recommended serving pistachio group (RSG) that consumed 42 g of 
pistachios daily, a high serving pistachio group (HSG) that consumed 70 g of pistachios 
daily, or a diet control group (DCG) that did not consume any pistachios.  Pistachios 
were to be consumed as an afternoon snack and participants were instructed to continue 
their usual activity patterns during the study period.  Results showed no significant 
changes in body weight (no data were provided for starting or ending weights), BMI 
(28.03 ± 4.35, 28.12 ± 3.22, and 28.01 ± 4.51 kg/m2 at baseline for the DCG, RSG, and 
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HSG groups, respectively; no data for ending values were provided) or waist-to-hip ratio 
(change of 0.01 ± 0.02, 0.01 ± 0.04, and 0.0 ± 0.03 for RSG, HSG, and DCG, 
respectively from baseline to week 12) over the course of a 12-week treatment period.  In 
this study, pistachio supplementation was not associated with any changes in measures of 
adiposity in participants with MetS when incorporated into a healthy diet.   
Four additional studies (two randomized crossover trials [Gebauer et al., 2008; 
Sheridan et al., 2007], one randomized control trial [Kocygit et al., 2006)], and one 
prospective study [Aldemir et al., 2011]) showed no significant changes in BMI 
following pistachio supplementation.   
Sheridan et al. (2007) investigated the effects of substituting 15% daily caloric 
intake worth of pistachios in place of fat or high fat snacks in a population of 15 men and 
women with primary, moderate hypercholesterolemia.  The intervention phase lasted 4 
weeks, and participants received pre-measured bags of pistachios matching their 
individual energy needs.  Because this was a crossover study, participants served as their 
own controls.  While on the control diet, participants consumed their normal, regular 
diets.  One-day food records each week were used to measure compliance.  Results 
showed that the BMI of participants following the conclusion of the pistachio diet (27.8 ± 
.81 kg/m2) and regular diet (27.7 ± 0.82 kg/m2) did not differ significantly from baseline 
(27.7 ± 0.90 kg/m2).  The difference in BMI between the pistachio group and baseline 
was 0.18 (-0.26 to 0.62) kg/m2 (p=0.39).  There was also no significant difference in BMI 
between the pistachio group and the regular group during the study (0.14 [-0.17 to 0.45] 
kg/m2, p=0.35).  Overall, pistachio consumption had no effects on BMI in men and 
women with primary, moderate hypercholesterolemia. 
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The randomized control trial by Kocygit et al. (2006) utilized 60 doctors and 
nurses at the Research Hospital, University of Harran, Sanliurfa, Turkey.  Participants 
were randomized into a pistachio treatment group (that consumed 20% [65 to 75 g/day] 
of their daily caloric intake from pistachios substituted for fatty foods and visible fats), 
and a regular diet group.  After a 1-week pre-experimental period (during which 
participants consumed their regular diet excluding any nuts, nut butters, or nut oils) the 
participants began a 3-week experimental period.  Participants in the regular diet group 
were to continue to exclude any nut-based products and participants in the pistachio 
group were encouraged to eat their nuts after dinner each day.  Physical activity was to 
remain constant throughout the study.  Each participant was provided a digital scale and 
education from a Registered Dietitian on how to complete food records, which were 
reviewed weekly.  Results showed that changes in BMI during the study were not 
significant.  The pistachio group had an average BMI of 24.2 ± 6.1 kg/m2 at baseline and 
24.3 ± 5.8 kg/m2 at the end of the study with a difference of 1.1 ± 0.2 kg/m2 (p>0.05).  
The regular diet group had an initial average BMI of 24.6 ± 5.6 kg/m2 and 24.5 ± 5.4 
kg/m2 at the end of the study with a difference of 0.9 ± 0.02 kg/m2 (p>0.05).  Pistachio 
supplementation in this healthy population was not associated with any change in BMI.   
Similarly, Aldemir et al. (2011) investigated the effects of pistachio consumption 
on BMI in 17 married men who had experienced erectile dysfunction for at least 12 
months.  This prospective study provided all participants with 20% (100 g, 570 kcals) of 
their daily caloric intake from pistachios for 3 weeks, which were to be consumed during 
lunchtime.  Participants were instructed to maintain normal patterns of physical activity 
and maintain their normal diets throughout the study.  The average baseline BMI of 
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participants was 27.33 ± 2.88 kg/m2 and did not change significantly after the pistachio 
intervention (no data for ending values were provided).  Pistachio supplementation in 
men with erectile dysfunction was not associated with any significant changes in BMI.   
Gebauer et al. (2008) studied the effects of the consumption of two different 
quantities of pistachios on body weight in 28 men and women with elevated LDL-C.  In 
this randomized crossover controlled feeding trial, subjects were randomly assigned to 
three treatment diets for 4 weeks each, which were separated by 2-week intervals.  Each 
feeding period had isocaloric diets at an average of 2500 kcal/day to maintain the weight 
of the participants.  The control diet followed the American Heart Association’s Step I 
diet, which contained low-fat or nonfat versions of typical American foods as well as 
fruits, vegetables, lean meats, and whole grains.  The pistachio diets contained either 10% 
(32 g to 63 g/day) or 20% (63 g to 126 g/day) kcals from pistachios based on daily energy 
needs.  While the pistachio diets were higher in protein and unsaturated fats and lower in 
carbohydrate and sodium than the control diet, all diets contained equal amounts of SFA 
and cholesterol.  All of the participants’ meals and snacks were made for them at the 
Metabolic Diet Study Center at the Pennsylvania State University.  Participants ate one 
meal per day at the Metabolic Diet Study Center Monday through Friday, and picked up 
the remainder of their pre-packaged meals for the rest of the week.  Daily questionnaires 
were used to ensure compliance.   
Results showed no significant difference in average body weight before versus 
after treatment (76.6 ± 2.5 kg and 76.1 ± 2.5 kg, respectively; p>0.05) or average BMI 
before versus after treatment (26.7 ± 0.7 kg and 26.6 ± 0.7 kg, respectively; p>0.05).  
There were also no significant differences in body weight or BMI when comparing the 
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control diet and pistachio diets (p>0.05; no other data were provided).  In this study 
pistachio supplementation was not associated with weight gain or changes in BMI among 
adults with elevated LDL-C.   
While body weight is not an accurate indicator of body composition, two 
additional studies showed non-significant changes in body weight following pistachio 
supplementation (Edwards et al., 1999; Sari et al., 2010).   
Edwards et al. (1999) studied the effects of a diet supplemented with 20% daily 
caloric intake from pistachios (substituted for fat calories or high fat snacks) on a 
population of 10 men and women with primary, moderate hypercholesterolemia.  This 
randomized crossover trial included a 3-week treatment period with no lag time between 
the control and treatment periods.  Throughout the study participants were encouraged to 
consume their normal diets, but to substitute pistachios for high fat foods when following 
the treatment diet.  Each week subjects kept one-day food records to ensure compliance 
and met with a dietitian weekly for education on substitutions.  Results showed that there 
were no significant changes in body weight during the study (no data were provided).  
Pistachio consumption was not associated with weight gain in participants with primary, 
moderate hypercholesterolemia. 
Likewise, Sari et al. (2010) examined the effects of pistachio consumption on 
body weight in 32 healthy young men ages 21 to 24 at a vocational police education 
school in Turkey where students lived and ate in a controlled environment.  This 
randomized control trial began with a 4-week phase where participants consumed a 
Mediterranean-type diet, which emphasized vegetables and fish and limited red meat, egg 
products, and products with high amounts of fat.  Following this period, participants 
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maintained the Mediterranean-type diet but replaced MUFA content with 20% daily 
energy needs from pistachios.  The two diets were isocaloric and equal in proportion of 
protein and carbohydrate but the pistachio diet contributed lower SFA and PUFA content 
plus higher MUFA and fiber content than the control diet.  A Registered Dietitian 
oversaw meal periods to ensure compliance, and collected and weighed leftover food for 
review by the researchers.   
Results showed that there were no significant differences in body weight 
throughout the study (p>0.1).  Average body weight at baseline was 69.3 ± 4.9 kg.  
Following the Mediterranean diet the average body weight of the participants was 69.7 ± 
5.0 kg and following the pistachio diet was 69.5 ± 5.1 kg.  When pistachios were added 
into a Mediterranean diet pattern no significant changes in body weight were observed.   
While Gulati et al. (2014) found significant reductions in WC and SCAT and Li et 
al. (2010) found significant reduction in body weight and BMI following pistachio 
consumption, the majority the of studies reviewed above found no significant changes in 
measures of adiposity in response to dietary pistachio supplementation.   
Of the nine studies that examined the effects of pistachio consumption on 
measures of adiposity, only two studies focused on healthy populations (Kocygit et al., 
2006; Sari et al., 2010).  Thus, there has been limited research to date that examines the 
effects of a pistachio-supplemented diet on measures of adiposity in healthy populations 
with normal body weights.  The intervention periods of the two studies that tested healthy 
populations lasted only 3 and 4 weeks and included only 32 and 44 participants, 
respectively (Kocygit et al., 2006; Sari et al., 2010).  Consequently, more studies with 
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longer intervention periods and greater numbers of participants are needed to support 
these findings. 
Effects on Blood Lipids 
Research has shown that pistachio consumption has beneficial effects on the 
blood lipid profile (Table 7).  Four randomized crossover trials (Baer et al., 2012; 
Edwards et al., 1999; Gebauer et al., 2008; Sheridan et al., 2007), five randomized 
controlled trials (Gulati et al., 2014; Kocygit et al., 2006; Li et al., 2010; Wang et al., 
2012; Sari et al., 2010), and one prospective study (Aldemir et al., 2011), have all 
detected positive impacts of pistachio consumption on blood lipids.  These studies have 
investigated both healthy and unhealthy populations including those with moderate 
hypercholesterolemia, elevated LDL-C, erectile dysfunction, MetS, and overweight or 
obesity.  The amount of pistachios consumed during treatment periods has ranged from 
42 g to 100 g and 10% to 20% of daily caloric intake.  All ten studies evaluated four 
parameters of the lipid profile: LDL-C, HDL-C, TC, and TAG.  Nine of these studies 
were reviewed in the previous section regarding their findings on measures of adiposity, 
therefore descriptions of their study methods can be found above. 
Baer et al. (2012) conducted a randomized crossover controlled feeding trial to 
study the effects of pistachio consumption on blood lipids in healthy adult men and 
women.  Participants were recruited from the Beltsville Human Nutrition Research 
Center in Maryland and were each fed two of three possible dose levels of pistachios for 
18 days each.  Each participant then repeated one of the two previously consumed dose 
levels for another 18 days based on random group assignments.  Doses were either a 0 
g/day control diet, a 42 g/day pistachio diet, or an 84 g/day pistachio diet.  Participant 
diets were controlled, isocaloric, based on weight maintenance, and consisted of typical 
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American foods in a 7-day cycle menu.  Participants were required to eat only food 
provided to them by the Beltsville Human Nutrition Research Center, where they 
consumed breakfast and dinner with a dietitian present to ensure compliance.  Lunch and 
weekend meals were provided for the participants to eat at home.  The background diet 
consisted of a fat to fiber ratio similar to that of nuts so that it would be constant across 
treatment groups.   
Results showed that pistachio supplementation had no significant effect on TC, 
HDL-C, or TAG (no data were provided); however, LDL-C levels were 6% lower after 
the 42g/day (123.9 ± 2.2 mg/dL) and 84g/day (123.4 ± 2.1 mg/dL) treatments compared 
to the control treatment (131.3 ± 2.2 mg/dL), with no additional reduction between the 42 
g/day and 84 g/day treatments (Baer et al., 2012).  This study showed that pistachio 
consumption was associated with improved LDL-C levels in healthy participants but not 
in a dose-dependent manner.   
The study by Edwards et al. (1999) found that after a 3-week intervention, a diet 
with 20% daily caloric intake from pistachios had positive impacts on blood lipids in 
participants with primary, moderate hypercholesterolemia.  Following the pistachio 
intervention there were significant decreases in TC (243 mg/dL at baseline versus 239 
mg/dL at the end of the study, p<0.04), TC/HDL-C (4.8 at baseline versus 4.5 at the end 
of the study, p<0.01), LDL-C/HDL-C (3.2 at baseline versus 3.1 at the end of the study, 
p<0.02); and a significant increase in HDL-C (50 mg/dL at baseline versus 56 mg/dL at 
the end of the study, p<0.09).  Results also showed that LDL-C decreased from 180 
mg/dL at baseline to 158 mg/dL at the end of the study, and that TAG decreased from 
113 mg/dL at baseline to 108 mg/dL at the end of the study; however, for both variables, 
48 
 
there was too much variation to assign a significant p-value.  While this study had a 
relatively short intervention period, significant changes in lipid values where still 
established among participants with primary, moderate hypercholesterolemia.   
The randomized crossover controlled feeding trial by Gebauer et al. (2008) also 
investigated the effects of pistachio consumption on lipid values.  Results showed that 
after 4 weeks, participants with elevated LDL-C on both treatment diets had significantly 
lower TC (193.7 ± 3.9 mg/dL for 10% the pistachio diet and 190.3 ± 3.9 mg/dL for the 
20% pistachio diet) compared to the control diet (209.6 ± 3.9 mg/dL) (p<0.001) and 
significantly lower LDL-C (119.1 ± 3.9 mg/dL for the 10% pistachio diet and 115.2 ± 3.9 
mg/dL for the 20% pistachio diet) compared to the control diet (132.3 ± 1.9 mg/dL) 
(p<0.001).  Additionally, TAG (p<0.01), TC/HDL-C (p<0.001), and LDL-C/HDL-C 
(p<0.001) were significantly lower following the 20% pistachio diet (106.3 ± 8.9, 3.5 ± 
0.19, and 2.15 ± 0.2 mg/dL, respectively) compared to the control diet (124.0 ± 8.9, 3.98 
± 0.19, and 2.55 ± 0.2 mg/dL, respectively).   
Total cholesterol/HDL-C and LDL-C/HDL-C were also significantly lower 
following the 20% pistachio diet (3.5 ± 0.19 and 2.15 ± 0.2 mg/dL, respectively) 
compared to the 10% pistachio diet (3.78 ±0.19 and 2.38 ± 0.2 mg/dL) (p<0.5), indicating 
a dose-dependent effect.  There were no significant differences in HDL-C between either 
of the two treatment diets (1.43 ± 0.1 mg/dL for the 10% pistachio diet and 1.48 ± 0.1 
mg/dL for the 20% pistachio diet) compared to the control diet (1.43 ± 0.3 mg/dL) 
(p>0.05).  Pistachio consumption beneficially impacted lipid status in those with elevated 
LDL-C and had a dose-dependent effect on TC/HDL-C and LDL-C/HDL-C.   
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In the randomized crossover trial by Sheridan et al. (2007) participants with 
primary, moderate hypercholesterolemia showed significant reductions in TC/HDL-C 
(4.4 ± 0.26 versus 4.8 ± 0.31 mg/dL; mean difference -0.38 [-0.57 to -0.19] mg/dL; 
p<0.001) and LDL-C/HDL-C (2.8 ± 0.25 versus 3.2 ± 0.26 mg/dL; mean difference -0.40 
[-0.66 to -0.15] mg/dL; p=0.004) and a significant increase in HDL-C (57 ± 3.5 mg/dL 
versus 54 ± 3.4 mg/dL; mean difference 2.3 [0.48 to 4.0] mg/dL; p=0.02) following 
treatment with 15% daily caloric intake from pistachios compared to the control diet. 
Results also showed nonsignificant reductions in TC (237 ± 8.0 versus 246 ± 8.7 
mg/dL; mean difference -9.2 [-21 to 2.4] mg/dL; p=0.11), TAG (131 ± 11 versus 130 ± 
14 mg/dL; mean difference 0.67 [-25 to 26] mg/dL; p=0.96), and LDL-C (148 ± 9.9 
versus 163 ± 9.3 mg/dL; mean difference -15 [-31 to 0.94] mg/dL; p=0.06) following the 
pistachio treatment compared to the control diet.  In only 4 weeks pistachio consumption 
improved TC/HDL-C, LDL-C/HDL-C, and HDL-C in patients with primary, moderate 
hypercholesterolemia despite nonsignificant changes in TC, TAG, and LDL-C.   
The randomized control trial by Gulati et al. (2014) found that among adults with 
MetS, a 24-week treatment consisting of 20% daily caloric intake from pistachios was 
associated with significant decreases in TC (174.5 ± 19 versus 185.5 ± 18.9 mg/dL; mean 
difference 10.5 [1.3 to 19.7] mg/dL; p=0.02) and LDL-C (98.8 ± 13.2 versus 107.7 ±13.2 
mg/dL; mean difference 8.9 [2.5 to 15.3] mg/dL; p<0.006), a nonsignificant increase in 
HDL-C (38.1 ± 5.4 versus 37.9 ± 5.4 mg/dL; mean difference -0.15 [2.8 to 2.5] mg/dL; 
p=0.9), and a nonsignificant decrease in TAG (153.5 ± 36.5 versus 159.7 ± 36.5 mg/dL; 
mean difference 6.1 [-11.6 to 23.8] mg/dL; p=0.5) in the intervention group compared to 
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the control group.  This relatively long intervention period yielded significant reductions 
in TC and LDL-C in patients with MetS.   
The randomized control trial by Wang et al. (2012) found significant decreases in 
TAG in participants with MetS from baseline to 12 weeks in the 42 g/day pistachio group 
(218.8 ± 113.4 versus 189.5 ± 91.2 mg/dL, respectively; mean difference -33.7 ± 70.0 
mg/dL; p=0.018), although the 70 g/day pistachio group did not show any significant 
changes in TAG from baseline to 12 weeks (194.0 ± 67.3 versus 181.6 ± 70.9 mg/dL; 
mean difference 15.9 ± 77.1 mg/dL).  Additionally, there were no significant differences 
from baseline to 12 weeks in TC within the 42 g/day diet group (204.6 ± 39.1 versus 
201.1 ± 36.3 mg/dL), the 70 g/day diet (204.6 ± 36.0 versus 209.2 ± 41.0 mg/dL), or the 
control diet (193.7 ± 38.2 versus 199.1 ± 40.2 mg/dL).  Likewise, there were no 
significant changes in HDL-C with the 42 g/day diet, the 70 g/day diet, or control diet 
(data not shown); however, there was a significant increase in LDL-C from baseline to 12 
weeks with both the 70 g/day diet (116.0 ± 27.1 versus 127.6 ± 30.2 mg/dL; mean 
difference 12.0 ± 19.7 mg/dL; p=0.003) and the control diet (104.4 ± 34.8 versus 115.6 ± 
33.3 mg/dL; mean difference 11.2 ± 28.6 mg/dL; p=0.037), but not with the 42 g/day diet 
(119.1 ± 27.1 versus 119.9 ± 26.7 mg/dL).  Despite increased LDL-C in the 70 g/day diet 
group, TAG values decreased significantly in participants with MetS following pistachio 
consumption.    
The randomized control trial by Kocygit et al. (2006) found that among healthy 
men and women, 20% daily caloric intake from pistachios was associated with significant 
decreases in TC (139.6 ± 23.2 versus 157.8 ± 26.7 mg/dL; mean difference -18.2 ± 3.5 
mg/dL; p<0.05), TC/HDL-C (3.17 ± 1.04 versus 3.98 ± 1.41; mean difference -0.81 ± 
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0.37; p<0.001), LDL-C/HDL-C (1.58 ± 0.47 versus 1.82 ± 0.51; mean difference -0.24 ± 
0.04; p<0.005), and a significant increase in HDL-C (49.5 ± 10.4 versus 39.1 ± 10.8 
mg/dL; mean difference 10.4 ± 0.39 mg/dL; p<0.005) from baseline to end of the 
pistachio treatment group.  There were also nonsignificant decreases in LDL-C (73.1 ± 
16.6 versus 75.0 ± 16.6 mg/dL; mean difference -1.9 ± 0.39 mg/dL) and TAG (94.8 ± 
41.6 versus 104.5 ± 52.3 mg/dL; mean difference -9.74 ± 1.8 mg/dL) from baseline to 
end of the pistachio treatment period. 
Significant differences were also found between the pistachio diet and the regular 
diet following the 3-week diet periods for TC (-10.4 [-0.77 to -19.7] mg/dL; p<0.05), 
HDL-C (7.34 [10.4 to 4.25] mg/dL; p<0.001), TC/HDL-C (-1.07 [0.58 to -1.56]; 
p<0.001), and LDL-C/HDL-C (-0.29 [0.12 to -0.47]; p<0.005).  Nonsignificant 
differences between diets were found for LDL-C (0.77 [-5.41 to -7.35] mg/dL) and TAG 
(-24.8 [0.89 to -59.3] mg/dL).  These results indicate that even in a healthy population, 
pistachio consumption may have the potential to improve the blood lipid profile.   
Sari et al. (2010) also found positive impacts on blood lipids in healthy young 
men.  Results showed significant decreases in LDL-C (124.5 ± 24.5 versus 95.0 ± 23.2 
mg/dL, respectively; p<0.001), TC (190.7 ± 30.1 versus 149.4 ± 26.5 mg/dL, 
respectively; p<0.001), TAG (112.1 ± 45.5 versus 91.1 ± 38.1 mg/dL, respectively; 
p=0.008), TC/HDL-C (4.40 ± 0.8 versus 3.78 ± 0.7 mg/dL, respectively; p<0.001), and 
LDL-C/HDL-C (2.88 ± 0.7 versus 2.3 ± 0.6 mg/dL, respectively; p<0.001) with the 
Mediterranean diet compared to the pistachio diet; but no significant change in HDL-C 
(43.5 ± 9.2 versus 41.7 ± 7.38 mg/dL, respectively; p=0.069).  This study supports 
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evidence that pistachio consumption may have beneficial impacts on lipid status in 
healthy adults.   
 The randomized control trial by Li et al. (2010) measured the difference in lipid 
values at weeks 0, 6, and 12 in a sample of overweight and obese adults following a 
weight loss diet.  The pistachio snack group compared to the pretzel snack group showed 
significant decreases in TAG at weeks 6 and 12.  Triacylglycerol values at week 6 were 
88.0 ± 9.8 mg/dL for the pistachio group and 144.6 ± 18.9 mg/dL for the pretzel group 
(p<0.05).  At 12 weeks, TAG values were 88.1 ± 6.8 mg/dL for the pistachio group 
versus 132.1 ± 16.8 mg/dL for the pretzel group (p<0.05).  Total cholesterol values were 
not significantly different between the pistachio group and pretzel group at week 12 
(191.6 ± 7.5 versus 183.2 ± 8.2 mg/dL, respectively), nor were values of LDL-C (79.9 ± 
11.0 versus 72.9 ± 10.7 mg/dL, respectively) or HDL-C (42.9 ± 2.5 versus 39.5 ± 2.5 
mg/dL, respectively).  This evidence suggests that when compared to a refined 
carbohydrate snack, pistachio consumption may have beneficial effects on TAG in obese 
adults.   
  Among adult men with erectile dysfunction, Aldemir et al. (2011) found that 
20% daily caloric intake from pistachios had positive effects on blood lipids.  After 3 
weeks, compared to baseline, there were significant decreases in TC (148.3 ± 38.9 versus 
179.5 ± 53.2 mg/dL, p=0.008), LDL-C (84.8 ± 10.1 versus 106.1 ± 30 mg/dL, p=0.007), 
TC/HDL-C (2.4 ± 0.6 versus 4.3 ± 1.4, p=0.001), LDL-C/HDL-C (1.4 ± 0.2 versus 2.6 ± 
0.8, p=0.001), TAG/HDL-C (2.1 ± 0.9 versus 4 ± 2.9, p=0.013), a significant increase in 
HDL-C (62.1 ± 7.9 versus 42 ± 6.4 mg/dL, p=0.001), and a nonsignificant decrease in 
TAG (133.9 ± 71.1 versus 160.8 ± 99 mg/dL, respectively; p=0.288).  Even a relatively 
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short intervention of 3 weeks was shown to significantly improve nearly all aspects of the 
lipid profile.   
Significant reductions in LDL-C were found in six out of ten studies and were 
present in populations with moderate hypercholesterolemia (Sheridan et al., 2007), 
elevated LDL-C (Gebauer et al., 2008), MetS (Gulati et al., 2014), erectile dysfunction 
(Aldemir et al., 2011), and in normolipidemic populations (Baer et al., 2012; Sari et al., 
2010) in interventions lasting 3 to 4 weeks.  Likewise, six out of ten studies showed 
significant reductions in TC in similar populations (Aldemir et al., 2011; Edwards et al., 
1999; Gebauer et al., 2008; Gulati et al., 2014; Sari et al., 2010; Kocygit et al., 2006) over 
the course of 3 to 4 weeks, as well as one intervention that lasted 24 weeks (Gulati et al., 
2014).   
Of the ten studies reporting improvements in the lipids profile, four showed 
significant increases in HDL-C in one population with moderate hypercholesterolemia 
(Edwards et al., 1999), one with elevated LDL-C (Gebauer et al., 2008), one with erectile 
dysfunction (Aldemir et al., 2011), and in one healthy population (Kocygit et al., 2006).   
Significant reductions in TAG were reported in four out of the ten studies 
including populations with elevated LDL-C (Gebauer et al., 2008), overweight or obesity 
(Li et al., 2010), MetS (Wang et al., 2012), and in a healthy population (Sari et al., 2010) 
with interventions ranging from 4 to 12 weeks.  The literature indicates that pistachios are 
not only beneficial to healthy populations but may be utilized as part of nutrition therapy 
for unhealthy populations as well.  Beneficial changes to the lipid profile occurred in as 
little as 3 weeks (Aldemir et al., 2011; Baer et al., 2012; Edwards et al., 1999; Kocygit et 
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al., 2006), indicating that it does not take a long-term intervention to see positive results 
from healthy lifestyle changes. 
Also shown in the studies above were significant reductions in the ratios of LDL-
C/HDL-C and TC/HDL-C following pistachio supplemented diets.  Of the six studies that 
evaluated the impact of pistachios on these ratios all of them found significant reductions 
in both LDL-C/HDL-C and TC/HDL-C (Aldemir et al., 2011; Edwards et al., 1999; 
Gebauer et al., 2008; Sari et al., 2010; Kocygit et al., 2006; Sheridan et al., 2007).  
Previous studies indicate that the ratios of LDL-C/HDL-C and TC/HDL-C are even better 
predictors of CVD than LDL-C alone (Edwards et al., 1999).   
With two exceptions, the intervention lengths of these ten studies were relatively 
short.  While one randomized controlled trial had a 24-week intervention period (Gulati 
et al., 2014) and two others utilized 12-week interventions (Li et al., 2010; Wang et al., 
2012), the duration of the interventions for the other seven studies were either 3 or 4 
weeks long (Aldemir et al., 2011; Baer et al., 2012; Edwards et al., 1999; Gebauer et al., 
2008; Sari et al., 2010; Kocygit et al., 2006; Sheridan et al., 2007).  Additionally, the 
sample sizes utilized in these studies were relatively small.  In all ten studies, sample 
sizes were composed of 90 participants or fewer with four studies containing samples 
sizes of fewer than 20 participants (Aldemir et al., 2011; Baer et al., 2012; Edwards et al., 
1999; Gebauer et al., 2008; Gulati et al., 2014; Li et al., 2010; Sari et al., 2010; Kocygit et 
al., 2006; Sheridan et al., 2007).  Because the existing literature is composed of studies 
with small sample sizes and short duration, larger controlled feeding studies are needed to 
ensure the accuracy of the results (London, Pawlak, Colby, Wall-Bassett, & Sira, 2013).   
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Rationale 
Pistachio consumption has been shown to have beneficial impacts on a variety of 
health indicators including oxidative status, inflammatory markers, glucose control, 
diabetes, hemodynamics, lipid status, and measures of adiposity.  As such, pistachio 
consumption may be a simple way to reduce risk for CVD through dietary modification.  
Previous studies have found that pistachio consumption increases HDL-C and decreases 
TC, LDL-C, TC/HDL-C, LDL-C/HDL-C, and TAG; however, research evaluating 
pistachios’ effects on lipid status has largely focused on unhealthy populations.   
Of the studies that have investigated the effects of pistachio consumption on 
measures of adiposity, none of these studies have assessed the impact of pistachio 
consumption on total body fat percentage or have used DXA for such measures.  
Therefore, research examining the effects of pistachio consumption on lipid status and 
measures of adiposity in healthy populations is lacking, and this study aims to address 
some of the current gaps in the literature. 
 
Objectives 
The objective of this research was to determine the impact of pistachio 
consumption on lipid status and measures of adiposity in a healthy population using a 
crossover design with two 10-week treatment periods: a pistachio diet (20% of kcals) and 
a no-pistachio control diet.  It is hypothesized that daily pistachio consumption will help 
improve lipid status and have little or no effect on measures of adiposity.    
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CHAPTER 3: MATERIALS AND METHODS 
Recruitment and Participants 
Female students from both California Polytechnic State University, San Luis 
Obispo (CP-SLO) and California State Polytechnic University, Pomona (CP-P) were 
recruited via email, flyers, and word of mouth.  Interested students were given a 
screening questionnaire (Appendix A) to determine if they were qualified to participate.  
Inclusion criteria were biological female, age 18 to 40 years old, and BMI 18.5 to 25 
kg/m2.  Exclusion criteria included non-Cal Poly students, males, BMI below 18.5 kg/m2 
or above 25 kg/m2, not liking pistachios, allergy to nuts, chronic disease of any kind, 
medications that affected fat malabsorption, laxative use, excessive alcohol consumption 
(more than 1 ounce of ethyl alcohol per day), pregnancy or plans for pregnancy, presence 
of pacemaker or metal pins/plates in the body, or elite athletes.   
Study participants were limited to the first 30 qualified female students enrolled at 
CP-SLO and the first 30 qualified female students enrolled at CP-P.   
 
Study Design 
This study utilized a crossover design with two 10-week treatment periods (20% 
of kcals from pistachios and a no-pistachio control diet) separated by a 15-week washout 
period.  The first treatment period occurred during fall quarter 2012 (September 2012 to 
December 2012) and the second treatment period occurred during spring quarter 2013 
(April 2013 to June 2013).  Half of the participants at each campus were randomized to 
the pistachio diet (20% of kcals to be included daily as snacks or with meals) and the 
other half were assigned to the control diet (maintained usual diets excluding nuts).  
During the washout period participants were asked to resume their usual diets.  During 
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the second treatment period, those who were following the pistachio diet during the first 
treatment transitioned to the control diet and those who were following the control diet 
during the first treatment transitioned to the pistachio diet.  Participants were provided 
with roasted, unsalted, shelled pistachios supplied by the American Pistachio Growers. 
 
Study Visits 
The participants met researchers on their respective campuses once a week for 10 
weeks during the first treatment period and once a week for 10 weeks during the second 
treatment period.  During these visits, participants on the pistachio diet picked up bags of 
pre-measured pistachios for the week and all participants submitted completed food 
records (Appendix B).  Additionally, at the beginning and end of each treatment period, 
participants had their height, body weight, WC, and total body composition measured; 
and had their blood drawn at the Student Health Center on each respective campus.  At 
CP-SLO total body composition was measured using DXA (Lunar, GE Healthcare).   
At the first study visit, all participants from both groups were educated on the 
U.S. Department of Agriculture’s MyPlate guidelines and how pistachios fit in a healthy 
diet.  They were also provided with recipe ideas of how to incorporate pistachios into 
their meals each day (Appendix C).  To determine the amount of pistachios each 
participant was to consume (20% of daily caloric need) researchers used the Harris-
Benedict Equation to determine the energy needs of each participant based on age, 
height, and body weight.  Physical activity questionnaires were also used to determine 
physical activity levels, which were considered when determining energy needs.  
Participants completed the 2002 International Physical Activity Questionnaire short form 
(Appendix D), which assessed physical activity level during the preceding 7 days, and 
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were counseled to maintain a constant level of physical activity throughout the study.  
Based on this information, pistachios were pre-measured weekly for each participant into 
individual bags, one for each day of the week.   
 
Food/Satiety Records 
Participants were asked to keep three sets of 3-day food records (9 records total) 
during each treatment period, for a total of 18 records per participant.  No food records 
were collected during the washout period.  Each set of food records began on a randomly 
assigned day throughout the quarter.  Participants were trained to accurately record 
different food components.  The participants’ diets were analyzed using the Nutrition 
Data System for Research (NDSR) version 2012, developed by the Nutrition 
Coordinating Center (NCC), University of Minnesota (Minneapolis, MN).  On each food 
record, participants filled out a numerical Hunger/Satiety rating (Appendix E) 
corresponding to their hunger level before, during, and after each meal.  Additionally, a 
validated Visual Analog Scale (VAS) (Appendix F) was used to measure the 
participants’ hunger and satiety ratings before and after consuming their meal or snack 
containing pistachios (for those on the pistachio diet) or a randomly chosen snack or meal 
(for those on the control diet).   
 
Compliance 
 Participants received an Unusual Diet Diary (Appendix G), on which they were 
instructed to record any accidental pistachio consumption, medications that were taken, 
or perceived side effects of nut consumption.  At each weekly meeting, participants 
returned all empty pistachio bags from the previous week to ensure adherence to the diet.  
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Both of these methods were utilized to assess compliance.  Additionally, prior to study 
visits participants received reminders via email regarding their appointment time and 
protocols for each visit.   
 
Anthropometric Measurements 
Total body fat percentage was measured at weeks one and 10 of each treatment 
period at the CP-SLO campus only using full-body DXA scans.  The scans were 
completed on-campus in the Nutrition DXA Lab.  Prior to the scan, participants were 
asked to fast for 4 hours; remove any metal objects, jewelry, and shoes; and to take a 
pregnancy test to eliminate the possibility of pregnancy.  Even though the radiation level 
of the DXA scan is low, all efforts were made to protect the safety of a potential fetus.  
Any participant with a positive test would have been disqualified.   
Body weight was recorded to the nearest 0.1 kg on a calibrated scale and height 
was recorded to the nearest 0.1 cm.  Because there were no differences in height for any 
of the participants, the first height measurement was used as a constant.  Body mass 
index was calculated as body weight (kg) divided by height (m) squared.  Trained 
researchers measured WC based on NHANES III standardized procedures using a 
flexible measuring tape to the nearest 0.1 cm.   
 
Biochemical Analysis 
Prior to blood draws participants were told to fast for 12 hours and consume 1.5 
cups of water the morning of the visit to prevent dehydration.  Blood samples were 
collected on each campus’ Student Health Center by trained phlebotomists at weeks one 
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and 10 of each treatment period.  A lipid panel including TC, LDL-C, HDL-C, and TAG, 
was processed for each sample at an off-campus laboratory site. 
 
Staff 
 Researchers at CP-SLO recruited 15 undergraduate research assistants from the 
Food Science and Nutrition Department to assist with pistachio delivery and bag pick-up 
as well as food record review and collection.  A Registered Dietitian trained all research 
assistants to evaluate the completeness of the food records and gave final approval on all 
food record completeness. 
 
Statistical Analyses 
 For statistical analysis JMP Pro 11 (Cary, NC) was used.  Separate mixed effects 
models were used to determine significant differences for each response variable (TC, 
TAG, LDL-C, HDL-C, TC/HDL, body weight, BMI, WC, and total body fat percentage) 
with the following predictors: campus (fixed effect; 2 levels – CP-SLO or CP-P), subject 
ID (random effect; 30 levels nested within each campus), diet (fixed effect; 2 levels – 
pistachio or habitual), visit (fixed effect; 2 levels – baseline and end of diet), diet*visit 
(interaction of diet and visit to determine if change in outcome from baseline to end 
depends on which type of diet), and diet*campus (interaction of diet and campus to 
determine if the diet had different effects for the two campuses, with regard to outcome 
of interest).  The only exception was the variable total body fat percentage which was not 
evaluated with regard to campus or diet*campus since data on total body fat percentage 
was only collected at CP-SLO.  A sample of 30 participants on each campus was 
expected to provide statistical power of 80%.   
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 Compensation 
Participants received a $10 university gift card following completion of the first 
treatment period and a second $10 university gift card following completion of the 
second treatment period.   
 
Ethical Approval 
All procedures involving human participants were approved by the Institutional 
Review Boards at both CP-SLO and CP-P.  Participants gave their signed informed 
consent prior to start of the study (Appendix H).    
 
Funding 
 This research was funded by the Agricultural Research Initiative (Grant #59654) 
and by the American Pistachio Growers (Grant #47031). 
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CHAPTER 4: RESULTS 
Participants 
At CP-SLO, 56 potential participants were screened, 33 of whom qualified for the 
study based on the screening questionnaire.  Before the start of the study, three 
participants dropped out (one cited family reasons and the two others underestimated 
their workload for the quarter and could not meet the time requirement).  At CP-P, 55 
potential participants were screened, 31 of whom qualified for the study.  Of those who 
qualified, one participant dropped out before the study began due to an adverse reaction 
to the initial blood draw.  Of the 60 total participants who were recruited from both 
campuses, 48 completed the study: 23 from CP-P and 25 from CP-SLO.  Reasons for 
dropout during the study included being put on medication, not answering emails, 
personal reasons, and stomach discomfort (Figure 6).   
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Figure 6.  Participant flow-charts from CP-SLO (top) and CP-P (bottom). 
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Baseline characteristics are shown in Table 8.  None of the characteristics listed 
were significantly different between participants at CP-P compared to participants at CP-
SLO. 
Table 8.  Participant baseline characteristics, mean ± SD. 
 
Characteristic  Cal Poly 
Pomona 
(n=23) 
Cal Poly SLO 
(n=25) 
Mean 
(n=48) 
P-value 
Age, years 22.8 ± 4.45 20.0  ± 1.47 21.0  ± 0.51        ----- 
Body weight, kg 60.2 ± 8.05 57.8 ± 7.30 58.9 ± 7.66 0.26 
BMI, kg/m2 22.0 ± 2.22 21.6 ± 2.21 21.9 ± 2.32 0.18 
WC, cm 186 ± 12.8 184 ± 18.8 185 ± 16.3 0.32 
TAG, mg/dL 79.0 ± 34.6 76.6 ± 38.5 77.7 ± 36.3 0.30 
TC, mg/dL 151 ± 30.8 159 ± 24.7 155 ± 27.7 0.06 
LDL-C, mg/dL 76.2 ± 23.1 79.0 ± 24.5 77.7 ± 23.6 0.24 
HDL-C, mg/dL 59.1 ± 13.4 64.3 ± 10.4 61.8 ± 12.1 0.22 
TC/HDL-C 2.64 ± 0.58 2.54 ± 0.62 2.59 ± 0.56 0.68 
Total body fat %a ----- 30.4 ± 4.29 -----        ----- 
aRegion % Fat from DXA 
 
Measures of Adiposity 
Results for BMI, body weight, and WC among all 48 participants and results for 
total body fat percentage among the 25 CP-SLO participants are shown in Table 9.  
There were no significant differences in any of the measures of adiposity between diet 
groups.   
 
 65 
 
Table 9.  Measures of adiposity at baseline and end of diet treatments, (n=48).   
aMixed effects model 
bLeast squares mean (standard error of the mean) 
cMixed effects model; Least squares mean and (standard error of the mean) 
dOnly tested at Cal Poly SLO (n=25)  
eRegion Fat % from DXA 
 
There were no significant differences in BMI between diet treatments (pistachio 
diet and control diet) (p=0.9).  Average BMI at baseline of the pistachio treatment was 
21.9 (0.06) kg/m2 and at the end of the pistachio treatment was 21.9 (0.07) kg/m2.  
Average BMI at baseline of the control treatment was 21.0 (0.07) kg/m2 and at the end of 
the control treatment was 21.9 (0.07) kg/m2.    
Similarly, there were no significant differences in body weight between diet 
treatments (pistachio diet and control diet) (p=0.8).  Average body weight at baseline of 
the pistachio treatment was 59.6 (0.26) kg and at the end of the pistachio treatment was 
59.4 (0.26) kg.  Average body weight at baseline of the control treatment was 59.1 (0.26) 
kg and at the end of the control treatment was 59.0 (0.26) kg.    
No significant differences in WC were found between diet treatments (pistachio 
diet and control diet) (p=0.4).  Average WC at baseline of the pistachio treatment was 
71.9 (0.36) cm and at the end of the pistachio treatment was 72.1 (0.36) cm.  Average 
WC at baseline of the control treatment was 72.4 (0.36) cm and at the end of the control 
treatment was 72.1 (0.36) cm.    
Measure of 
Adipositya 
Pistachio 
Baselineb 
Pistachio 
Endb 
Control 
Baselineb 
Control 
Endb 
P-value 
BMI, kg/m2 21.9 (0.06) 21.9 (0.07) 21.9 (0.07) 21.9 (0.07) 0.9 
Body weight, kg 59.6 (0.26) 59.4 (0.26) 59.1 (0.26) 59.0 (0.26) 0.8 
WC, cm 71.9 (0.36) 72.1 (0.36) 72.4 (0.36) 72.1 (0.36) 0.4 
Total body fat c,d,e, 
% 
30.2 (0.28) 30.2 (0.29) 30.0 (0.29) 30.0 (0.30) 0.9 
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Additionally, there were no significant differences in total body fat percentage 
between diet treatments (pistachio diet and control diet) (p=0.9).  Average total body fat 
percentage at baseline of the pistachio treatment was 30.2 (0.28)% and at the end of the 
pistachio treatment was 30.2 (0.29)%.  Average total body fat percentage at baseline of 
the control treatment was 30.0 (0.30)% and at the end of the control treatment was 30.0 
(0.30)%.    
No significant differences were found in any measures of adiposity between 
baseline and end of the pistachio diet or between baseline and end of the control diet 
(Figure 7).    
 
 
Least squares mean (standard error of the mean); pistachio diet 
Least squares mean (standard error of the mean); control diet 
 
Figure 7.  Measures of adiposity at baseline and end of diet treatments. 
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Blood Lipids  
Results for TAG, TC, LDL-C, HDL-C, and TC/HDL-C among all 48 participants 
are shown in Table 10.  There were no significant differences in any of the blood lipid 
variables between diet groups.   
Table 10.  Blood lipids at baseline and end of diet treatments, (n=48).   
 
Blood Lipid 
Variablesa 
Pistachio 
Baselineb 
Pistachio 
Endb 
Control 
Baselineb 
Control 
Endb 
P-value 
TAG, mg/dL 80.8 (3.43) 80.8 (3.57) 82.0 (3.38) 86.0 (3.46) 0.6 
TC, mg/dL 158 (1.90) 161 (1.88) 161 (1.88) 162 (1.90) 0.5 
LDL-C, mg/dL 79.4 (1.64) 82.1 (1.73) 81.5 (1.64) 81.5 (1.66) 0.4 
HDL-C, mg/dL 62.8 (0.90) 63.3 (0.95) 63.6 (0.90) 63.8 (0.91) 0.9 
TC/HDL-C 2.59 (0.04) 2.62 (0.04) 2.61 (0.04) 2.61 (0.04) 0.7 
aMixed effects model 
bLeast squares mean and (standard error of the mean) 
 
There were no significant differences in TAG between the pistachio and control 
diets (p=0.6).  The average TAG value at baseline of the pistachio diet was 80.8 (3.43) 
mg/dL and after the pistachio diet was 80.8 (3.57) mg/dL.  At baseline of the control diet 
average TAG value was 82.0 (3.38) mg/dL and after the control diet was 86.0 (3.46) 
mg/dL.   
Additionally, there were no significant differences in TC between the pistachio 
and control diets (p=0.5).  The average TC value at baseline of the pistachio diet was 158 
(1.90) mg/dL and after the pistachio diet was 161 (1.88) mg/dL.  At baseline of the 
control diet average TC value was 161 (1.88) mg/dL and after the control diet was 162 
(1.90) mg/dL.   
No significant differences in LDL-C were found between the pistachio and 
control diets (p=0.4).  The average LDL-C value at baseline of the pistachio diet was 79.4 
(1.64) mg/dL and after the pistachio diet was 82.1 (1.73) mg/dL.  At baseline of the 
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control diet average LDL-C value was 81.5 (1.64) mg/dL and after the control diet was 
81.5 (1.66) mg/dL.   
Likewise, there were no significant differences in HDL-C between the pistachio 
and control diets (p=0.9).  The average HDL-C value at baseline of the pistachio diet was 
62.8 (0.90) mg/dL and after the pistachio diet was 63.3 (0.95) mg/dL.  At baseline of the 
control diet average HDL-C value was 63.6 (0.90) mg/dL and after the control diet was 
63.8 (0.91) mg/dL. 
There were no significant differences in TC/HDL-C between the pistachio and 
control diets (p=0.7).  The average TC/HDL-C value at baseline of the pistachio diet was 
2.59 (0.04) and after the pistachio diet was 2.62 (0.04).  At baseline of the control diet 
average TC/HDL-C value was 2.61 (0.04) and after the control diet was 2.61 (0.04). 
No significant differences were found from baseline to the end of the control 
treatment or from baseline to the end of the pistachio treatment among any of the blood 
lipid variables (Figure 8).   
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Least squares mean (standard error of the mean); pistachio diet 
Least squares mean (standard error of the mean); control diet 
 
1TC, total cholesterol; TAG, triacylglycerol; LDL-C, low-density lipoprotein cholesterol; 
HDL-C, high-density lipoprotein cholesterol; TC/HDL-C, total cholesterol/high-density 
lipoprotein cholesterol 
 
Figure 8.  Blood lipids at baseline and end of diet treatments
1
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CHAPTER 5: DISCUSSION 
This study examined the effects of pistachio consumption on measures of 
adiposity and blood lipids in a 10-week crossover trial with two treatment groups (a 20% 
kcal per day pistachio diet and a control diet).  Pistachio consumption was not associated 
with significant changes in lipid profile (TC, TAG, LDL-C, HDL-C, or TC/HDL) or 
measures of adiposity (body weight, BMI, WC, or total body fat percentage).  Similarly, 
no changes were observed in the control group or between the two diets for any variable. 
This study is unique compared to previous research for a number of reasons.  
First, the sample of participants in this study was composed of healthy, young female 
college students.  To date only two previous studies have investigated the effects of 
pistachio consumption in healthy populations with a normal BMI, and of those, one study 
tested only male subjects (Sari et al., 2010) and the other tested both male and female 
subjects (Kocygit et al., 2006).  Therefore, this is the first study to evaluate the effects of 
pistachio consumption on healthy young (average of less than 25 years of age) females 
with an average healthy BMI.   
Additionally, while three previous pistachio consumption studies incorporated 
treatment periods of 12 weeks or longer (Gulati et al., 2014; Li et al., 2010; Wang et al., 
2012), the 10-week treatment period of this study was substantially longer than the 
majority of previous studies, which have consisted of treatment periods of 3 to 4 weeks 
(Aldemir et al., 2011; Baer et al., 2012; Edwards et al., 1999; Gebauer et al., 2008; 
Kocygit et al., 2006; Sari et al., 2010; Sheridan et al., 2007).  The longer treatment period 
provided more opportunity for the potential impacts of pistachio consumption to become 
apparent.  This study also utilized a sample size of 48, the fourth highest to date among 
pistachio feeding studies that evaluated blood lipids or measures of adiposity.  The 
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relatively larger sample size of this study increased its power to detect individual 
changes.   
This study is also distinctive in that only two previous studies have examined the 
effects of pistachio consumption on measures of adiposity other than body weight or 
BMI, and neither have done so in healthy populations (Gulati et al., 2014; Wang et al., 
2012).  This is the first study to evaluate the effects of pistachio consumption on total 
body fat percentage in any population.  While Gulati et al. (2014) evaluated WC, SCAT, 
and IAAT, and Wang et al. (2012) evaluated waist-to-hip ratio, no previous pistachio 
feeding studies have assessed total body fat percentage nor utilized DXA to do so.  This 
is only the second study to evaluate WC and the first to do so in a healthy population. 
 
Measures of Adiposity 
Participants did not show any significant differences in any measure of adiposity 
(body weight, BMI, WC, or total body fat percentage) during the pistachio treatment or 
the control treatment.  These findings are fairly consistent with the findings of previous 
pistachio intervention trials.  All but one (Li et al., 2010) of the nine previous studies 
evaluating the effects of pistachio consumption on body weight and/or BMI found no 
significant changes in either variable (Aldemir et al., 2011; Edwards et al., 1999; Gebauer 
et al., 2008; Gulati et al., 2014; Kocygit et al., 2006; Sari et al., 2010; Sheridan et al., 
2007; Wang et al., 2012).  While Li et al. (2010) did find significant changes in body 
weight and BMI from baseline to the end of each diet treatment (pistachio or pretzel), 
participants in each diet group were also on weight reduction diets, and no significant 
changes in body weight were found between treatment groups.  Participants on the 
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pistachio diet did, however, showed significantly lower BMI compared to the pretzel 
group at all but one two-week checkpoint.   
 Only the randomized control trial by Gulati et al. (2014) evaluated the effects of 
pistachio consumption on WC and found a significant decrease in WC in the intervention 
group compared to the control group.  However, the study sample included participants 
with MetS and an average BMI in the obese category, compared to the sample of the 
current study with no indicators of MetS and an average BMI in the normal range.  With 
less or no weight to lose, changes in WC may not have been as likely to occur in this 
sample.  Additionally, the significant changes in WC previously found occurred 
following an intervention of 24 weeks compared to the current intervention of only 10 
weeks; therefore, it is possible that significant changes in WC may take longer than 10 
weeks to occur.    
 Though no previous research has evaluated the effects of pistachio consumption 
on total body fat percentage, Gulati et al. (2014) found no significant changes in SCAT or 
IAAT in the pistachio group versus the control group, similar to the lack of significant 
changes in total body fat percentage found in this study.   
 Large epidemiological studies have also found limited effects of nut consumption 
on measures of adiposity.  In a review study, Natoli and McCoy (2007) showed that of 
the five major epidemiological studies that have evaluated the effects of nut consumption 
on body weight or BMI, only the California Seventh Day Adventist Health Study showed 
a statistically significant negative association between nut consumption and BMI (Fraser 
et al.  1992).  The Iowa Women’s Health Study (Ellsworth, Kushi, & Folsom, 2001) and 
Nurses’ Health Studies (Hu et al., 1998; Jiang, Manson, Stampfer, Liu, Willett, & Hu, 
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2002) found non-statistically significant trends with higher nut consumption and lower 
BMI, and the Physicians’ Health Study found no association between nut consumption 
and BMI (Albert, Gaziano, Willett, & Manson, 2002).  These findings suggest that 
frequent nut consumers (5 servings/week or more) do not have statistically significant 
differences in body weight or BMI compared to infrequent nut consumers (less than one 
serving/week) (Natoli & McCoy, 2007), similar to the findings from the current study.   
To date three principal mechanisms have been proposed describing the impact of 
nuts on weight gain despite their high-fat, energy-dense composition, including their 
satiety properties, lack of bioaccessibility, and potential to increase energy expenditure.  
First, in terms of the satiety properties of nuts, Mattes, Kris-Etherton, & Foster (2008) 
determined that 55-75% of the energy from nuts is offset by a reduction in subsequent 
energy intake.  Not only are nuts energy-rich and contain a variety of nutrients including 
protein, fiber, and unsaturated fats, they also require significant mastication, which helps 
to signal satiation through various sensory pathways (Mattes & Dreher, 2010).  While not 
the primary focus of this thesis, the effect of pistachios on satiety was illustrated by other 
data from the current study which found that participants felt more full, were not as 
hungry, and had fewer cravings while on the pistachio diet compared to the control diet 
(Burns-Whitmore, Hall, Towne, Bushnell, & Roy, 2014).  Interestingly, the current study 
also found that overall energy intake was significantly higher on the pistachio diet 
compared to the control diet (p=0.0012, data not shown).  This suggests that participants 
may have added, rather than substituted pistachios into their diets, yet participants still 
showed no significant change in total body fat percentage, body weight, BMI, or WC 
between the two diet treatments.  Despite other plausible explanations for this result such 
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as increased physical activity while on the pistachio diet or inaccurate food record 
completion, this finding supports the hypothesis that the energy in pistachios may not be 
fully absorbed.   
Secondly, it has been estimated that 10-15% of the energy in nuts is lost in the 
feces (Mattes et al., 2008).  One study by Ellis et al. (2004) determined that the 
intracellular lipids found in almonds are not fully bioaccessible during human digestion.  
The lipids are excreted leading to lower energy absorption than expected based on the 
quantity of nut consumed.  Additionally, by comparing energy excretion during pistachio 
diet treatments versus a control diet treatment, Baer et al. (2012) found that the energy 
density of pistachios was 5% less than the generally accepted value based on the Atwater 
principle that assumes a constant 10% of food remains undigested after passing through 
the gut (Mattes & Dreher, 2010).   
Thirdly, while the literature remains inconclusive, nut consumption may increase 
metabolic energy expenditure, which could offset energy contribution by as much as 10% 
(Mattes & Dreher, 2010).  Therefore, issues associated with bioaccessibility, satiety 
properties, and energy expenditure may have contributed to the observed null measures 
of adiposity following increased energy consumption on the pistachio diet compared to 
the control diet in the current study.   
These properties, coupled with the nutrient-rich composition of nuts suggest that 
nuts may yield nutritional benefits while not having observable impacts on body weight 
or body composition. 
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Blood Lipids 
Over the course of the 10-week treatment periods in the current study, participants 
did not show any significant differences in any blood lipid variables (TC, TAG, LDL-C, 
HDL-C, or TC/HDL) during the pistachio treatment compared to the control treatment.  
These results contrast the literature, which overwhelmingly shows the effects of pistachio 
consumption on blood lipids to be favorable.  Notably, all six studies that have evaluated 
the effects of pistachio consumption on TC/HDL-C have found significant reductions 
following the pistachio treatment period (Aldemir et al., 2011; Edwards et al., 1999; 
Gebauer et al., 2008; Sari et al., 2010; Kocygit et al., 2006; Sheridan et al., 2007).  The 
majority of studies have also found significant improvements in TC (Aldemir et al., 2011; 
Edwards et al., 1999; Gebauer et al., 2008; Gulati et al., 2014; Kocygit et al., 2006; Sari 
et al., 2010) and LDL-C (Aldemir et al., 2011; Baer et al., 2012; Gebauer et al., 2008; 
Gulati et al., 2014; Sari et al., 2010; Sheridan et al., 2007) following the pistachio 
treatments, while improvements in HDL-C (Aldemir et al., 2011; Edwards et al., 1999; 
Kocygit et al., 2006; Sheridan et al., 2007) and TAG (Gebauer et al., 2008; Sari et al., 
2010; Li et al., 2010; Wang et al., 2012) have occurred but less frequently. 
 In addition to the positive effects of pistachio intervention trials on TC and LDL-
C, clinical trials involving the consumption of other types of nuts have supported these 
findings.  A review of 23 human intervention trials found significant reductions in TC 
(between 2 and 16%) and LDL-C (between 2 and 19%) following interventions with 
various types of nuts including almonds, peanuts, pecans, and walnuts, but found that the 
effects of nut consumption on HDL-C and TAG were less consistent (Mukuddem-
Petersen, Oosthuizen, & Jerling, 2005).  Similarly, Griel and Kris-Etherton (2006) 
reviewed the effects of 15 clinical trials involving tree nuts (including walnuts, almonds, 
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pecans, macadamia nuts, pistachios, and hazelnuts) and found that the greatest 
improvements in the lipid profile were in LDL-C.  This review established that tree nut-
containing diets yielded a 13 mg/dL reduction in LDL-C in comparison to a usual diet 
and a 9 mg/dL reduction in comparison to a Step I Diet (Griel & Kris-Etherton, 2006).   
 While long-term prospective epidemiological studies have not specifically 
evaluated the effects of nut consumption on lipid profile, the beneficial association 
between nut consumption and CVD is well established.  A review of five large 
epidemiological studies revealed that after accounting for all possible confounding 
factors, the risk of CHD, nonfatal MI, fatal CHD, and sudden cardiac death decreased in 
a dose-dependent manner with frequency of nut consumption (from <1 time/week to ! 5 
times /week).  This equated to an 18-51% reduced risk of CHD in those who consumed 
nuts more than 5 times/week (Kris-Etherton, Zhao, Binkoski, Coval, & Etherton, 2001).  
While the literature is consistent in showing the beneficial effects of nut consumption on 
the lipid profile and CVD risk, the current study could not replicate these findings.   
 
Explanation of Findings 
 While the findings of the current study relating to measures of adiposity reflect 
those found in both short-term clinical and long-term epidemiological studies, the lack of 
significant findings related to blood lipids differs from the current state of research 
involving both pistachios and other types of nuts.  Despite utilizing a longer intervention 
period with a greater number of participants with a similar intervention (20% daily intake 
worth of pistachios) compared to previous studies that have found significant changes in 
blood lipids between diet groups (Aldemir et al., 2011; Baer et al., 2012; Edwards et al., 
1999; Gebauer et al., 2008; Gulati et al., 2014; Kocygit et al., 2006; Li et al., 2010; Sari et 
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al., 2010; Sheridan et al., 2007; Wang et al., 2012), this study revealed no significant 
changes in blood lipids.   
The demographics of the sample of participants in this study may be a 
contributing factor to the lack of significant changes.  The sample population of the 
current study had a mean age of 21 ± 0.51 years, average BMI of 21.9 ± 2.32 kg/m2 
(normal), average TC of 155.0 ± 27.7 mg/dL (desirable), and average LDL-C of 77.7 ± 
23.6 mg/dL (optimal), making this an extremely healthy population.  Additionally, the 
sample consisted of all females and all participants were students at either CP-SLO or 
CP-P.  Based on the demographics listed above, a number of potential factors exist that 
may have reduced the likelihood of observable changes to the lipid profile in this sample.   
Firstly, many previous studies have focused on populations with unhealthy lipid 
values, whereas the sample from the current study had healthy lipid values at the 
beginning of the study, leaving less opportunity for changes to be observed during the 
intervention period.  Of the ten previous pistachio consumption studies that have 
examined blood lipids, two have examined populations with primary, moderate 
hypercholesterolemia (Edwards et al., 1999; Sheridan et al., 2007), one has examined a 
population with elevated LDL-C (Gebauer et al., 2008), two studied populations with 
MetS (Gulati et al., 2013; Wang et al., 2012), and even among the remaining studies 
citing no overarching dyslipidemia among their respective samples, many of the samples 
had baseline cholesterol or LDL-C values that are considered borderline high or above 
optimal.  Previous intervention studies involving physical activity have found that 
participants with higher baseline TAG concentrations showed larger reductions in TAG 
levels following exercise training compared to subjects with low baseline TAG 
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concentrations (Fletcher et al., 2005).  If the same concept is applied to dietary 
interventions then the lack of significant changes in the lipid profile in this study may 
have been a result of the optimal starting values of the current sample.   
 A second explanation for the lack of significant changes may be that the 
participants already consumed a healthy diet, thereby diluting the beneficial effects of 
pistachio consumption.  Previous studies have theorized that the beneficial effects of 
pistachio consumption are based heavily on the pistachio’s nutritional components such 
as unsaturated fatty acids, fiber, phytochemicals, vitamins, and minerals (Dreher, 2012). 
Additionally, the positive effects many of these dietary components on the lipid profile 
have been well established (Appel et al., 2005), meaning that an optimal diet at baseline 
may have muted any potential effects of the pistachios. 
The sample of the current study included all female college students and many of 
the participants were studying nutrition (based on a questionnaire provided at the 
beginning of the study).  Based on previous research these criteria support the idea that 
this sample of participants consumed a diet higher in beneficial nutrients compared to the 
average population.  It is well documented that females consume more fruits and 
vegetables compared to men, which contain vitamins, minerals, phytochemicals, and 
fiber.  As of 2005, 20.3% of men consumed fruits and/or vegetables five or more times a 
day compared to 29.6% of women (Blanck, Gillespie, Kimmons, Seymour, & Serdula, 
2008), and in 2009-2010, among men aged 20 to 39, 33.2% consumed nuts compared to 
36.8% of women in the same age group (Nielsen, Kit, & Ogden, 2014).  While the 
current study was composed entirely of women, previous pistachio intervention trials 
have either included or have been composed entirely of men (Aldemir et al., 2011; Baer 
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et al., 2012; Edwards et al., 1999; Gebauer et al., 2008; Gulati et al., 2013; Kocygit et al., 
2006; Li et al., 2010; Sari et al., 2010; Sheridan et al., 2007; Wang et al., 2012).  The 
gender composition of such samples may have contributed to a lower overall diet quality, 
leaving greater opportunity for beneficial changes in the diet from pistachio 
supplementation to improve the lipid profile. 
Additionally, people who are more educated tend to consume a better quality diet.  
Darmon & Drewnowski (2008) found that measures of socioeconomic status including 
education showed a consistent positive association with multiple measures of diet quality 
including intake of fiber and other nutrients as well as certain plasma biomarkers.  This 
finding held true in multiple countries including the United States, Canada, and Australia.  
While data on the education level of participants in previous studies was not provided, in 
the United States between 2009 and 2013 only 28.8% of adults aged 25 years and older 
achieved a bachelor’s degree or higher (U.S. Census Bureau, 2015), whereas the 
participants in the current sample were all in the process of completing their bachelor’s 
degree.  Therefore, due to their education level, the participants in the current study may 
have a better overall diet quality compared to participants from similar studies.   
Furthermore, many previous pistachio consumption studies have included 
samples that were suffering from a medical issue like overweight or obesity (Li et al., 
2010), MetS (Gulati et al., 2013; Wang et al., 2012), or hypercholesterolemia (Edwards et 
al., 1999; Sheridan et al., 2007), making it reasonable to assume that the diet quality of 
these participants prior to the beginning of the studies was not ideal.  Conversely, all of 
the participants chosen for this sample were in good health and many were studying 
nutrition at either CP-SLO or CP-P, which may have increased their nutrition knowledge 
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compared to previously studied populations, leading them to consume a more nutrient 
rich diet.  Therefore, the beneficial components of pistachios may have yielded a greater 
impact on those individuals with poorer diet quality compared to the current sample that 
likely maintained a healthier diet. 
 Another possible explanation for the lack of significant changes in the current 
study is that this sample was relatively homogenous compared to previous pistachio 
feeding studies.  Most notably, the age range of previous pistachio interventions have 
spanned over 30 years (Baer et al., 2012; Edwards et al., 1999; Li et al., 2010; Sheridan et 
al., 2007), and with the exception of one study composed of all males (Sari et al., 2010), 
these studies have all been mixed gender (Aldemir et al., 2011; Baer et al., 2012; 
Edwards et al., 1999; Gebauer et al., 2008; Gulati et al., 2013; Kocygit et al., 2006; Li et 
al., 2010; Sheridan et al., 2007; Wang et al., 2012).  Similarly, the range of baseline lipid 
values in many previous studies has been broad.  For example, the baseline TC values in 
one pistachio treatment study of adults with hypercholesterolemia ranged from 214 to 
336 mg/dL (Edwards et al., 1999), which spans the “borderline high” and “high” risk 
categories.  Another pistachio treatment study among “healthy adults” cited LDL-C 
values at baseline from 80 to 183 mg/dL (Baer et al., 2012), which spans categories of 
“desirable,” “near optimal/above optimal,” “borderline high,” and “high risk.” 
Conversely, in the current study, all participants had baseline TC values in the 
“desirable” range except for 4 participants in the “borderline high” range.  Similarly, all 
participants in the current study had baseline LDL-C values in the “desirable” or “near 
optimal” categories, with 40 out of 48 participants having LDL-C values in the 
“desirable” category.  Previous pistachio feeding studies have utilized samples with 
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greater variation in baseline lab values and anthropometric characteristics compared to 
the relatively homogenous sample utilized in this study.  A more heterogeneous sample 
may have provided more opportunity for changes to occur during the intervention 
periods.   
 
Strengths and Limitations 
 This study followed a crossover design, which allowed each participant to serve 
as their own control thereby decreasing variability between participants in each treatment 
group.  Another strength of the study was that participants in the pistachio group were 
given individually labeled, pre-measured bags of pistachios for each day of the week.  
This helped participants keep track of their intake and made sure that participants 
consumed the proper quantity of pistachios each day.  All empty pistachio bags were 
collected at the end of each week to help ensure compliance.  Additionally, the use of 
DXA provided a high level of precision in determining total body fat percentage 
(Rothney et al., 2012). 
 One limitation of this study is the relatively small sample size.  While the sample 
size of this study was larger than that of most previous pistachio feeding studies, a larger 
sample size may have yielded more power to detect significant results.  Initially, a power 
of 80% to predict individual changes was based on a sample size of 30 participants per 
study site; however, due to loss of follow-up, CP-SLO and CP-P only retained 25 and 23 
participants, respectively, thereby decreasing the power of the study.   
Additionally, while previous studies have shown significant changes in blood 
lipids in as little as 3 weeks (Aldemir et al., 2011; Baer et al., 2012; Edwards et al., 2009; 
Kocygit et al., 2006), a longer intervention period may have provided more time for 
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changes to occur in this specific sample.  The only pistachio feeding studies that have 
shown significant changes in measures of adiposity utilized intervention periods spanning 
12 weeks or more.   
 Because this was a free-living study design researchers expected that participants 
consumed all of the pistachios they were given.  Despite measures to account for empty 
bags there was no way to guarantee that participants actually consumed all required 
servings of pistachios.   
 
Future Research 
While historically there has been concern for the relatively high fat content of 
nuts and subsequent impacts on blood lipids, body weight, and CVD risk (Hu, 2003), this 
study is part of the large body of literature that has helped to dispel that notion.  This 
study showed that consuming 20% of energy per day worth of pistachios did not 
negatively impact the lipid profile and was not associated with changes in measures of 
adiposity.  While previous research is fairly consistent in highlighting the beneficial 
effects of nut consumption on the lipid profile and thus on CVD risk, this study cannot 
confirm these findings.   
Therefore, future research may benefit from utilizing a greater number of 
participants, more diversity and heterogeneity in study participants, and longer treatment 
periods.  Including a greater number of participants will help increase statistical power, 
and longer treatment periods will help determine the longer-term effects of pistachio 
consumption in conjunction with other dietary variables, and help determine the limits of 
improvements in the lipid profile based on pistachio consumption.  Implementing a 
controlled feeding design is also beneficial to more effectively monitor energy intake, 
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account for variations in the background diet, and to ensure that participants adhere to 
their assigned dietary interventions.  Future nut intervention studies should attempt to 
have participants complete food records and conduct nutrient analyses to help determine 
any significant changes in diet quality due to nuts.  This will help confirm and/or provide 
new information on particular dietary components found in pistachios that are responsible 
for beneficial changes in health.   
Due to the increased risk of CVD with age (Odden et al., 2011) future pistachio 
intervention trials may find it useful to focus on the effects of pistachio consumption on 
blood lipids in elderly populations both with and without dyslipidemia.  Additionally, 
because results have been mixed among previous studies targeting young, healthy 
populations, follow-up studies should continue to evaluate this demographic to determine 
if pistachio consumption provides any significant health benefits in already healthy 
populations.   
While previous research has focused heavily on the ability of nuts to prevent 
CVD and other diseases, far less research has studied the potential of nuts to treat CVD.  
In certain cases plant-based diets have been shown to be as effective at reducing LDL-C 
as lipid lowering medication, with lower costs and fewer side effects (Rosenthal, 2000).  
Therefore, future intervention trials should be conducted in patients who have already 
suffered a cardiovascular event to determine the potential of nuts to protect against a 
second incident.  If such research yields positive results then pistachio consumption may 
be a relatively inexpensive and noninvasive way to help manage the lipid profile and 
reduce the risk of subsequent cardiovascular events without relying exclusively on 
medications.    
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While many large epidemiological studies have made the association between nut 
consumption and CVD risk (Mukuddem-Petersen et al., 2005), associations between nut 
consumption and the lipid profile have not been established in long-term prospective 
cohort studies, despite being widely studied in short-term clinical trials.  Longer-term 
evaluations of the effects of pistachios on the lipid profile may be an area for future 
research.  Additionally, large epidemiological studies often are not specific to the type of 
nut consumed, which may be a helpful addition to future research.  Lastly, because 
childhood obesity has become so prevalent (Must & Strauss, 1999) prospective cohort 
studies in children would be beneficial in determining if nut consumption at a young age 
is preventative against overweight or obesity as a teenager or young adult. 
Because there is still some uncertainty as to the mechanisms behind the effects of 
pistachio consumption (and nut consumption in general) on blood lipids and measures of 
adiposity, future research should continue to focus on this area.  Studies suggest that TC 
and LDL-C levels following nut consumption are 25% lower than would be predicted if 
the effect were due to the fatty acid composition of the nuts alone (Griel & Kris-Etherton, 
2006).  The extent to which various nutritional components of pistachios play a role in 
lipid lowering is unknown, therefore more mechanistic research is needed to determine 
which nutrients found in pistachios are most important for improving health.   
The potential of nuts to increase energy expenditure has also been controversial 
and more research is needed to determine the validity of past results.  Similarly, more 
research is needed on the satiety properties of nuts and how this information may be used 
to promote health.  Research comparing the satiety properties of nuts to other snack foods 
may help provide useful dietary advice to help maintain a healthy weight. 
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C. Pistachio Recipe Ideas 
How to Incorporate Pistachios Into Your Everyday Diet!  
 
For breakfast: 
 
Sprinkle them on top of your favorite… 
  
 Cereal 
Yogurt 
 Oatmeal 
 
Blend them into your favorite… 
 
 Smoothie (You won’t even know they are there!) 
  
For lunch or dinner: 
 
Chop them up and make a delicious crust for… 
  
 Tofu 
 Chicken 
 Fish 
 
Mix them into your favorite… 
 
 Salad  
 Fruit salad 
Sautéed vegetables or greens 
Stir-fry 
Rice dish 
Pasta dish 
 
For a snack: 
 
Mix with dry fruit for a delicious… 
 
 Trail mix (But be sure not to add any other nuts!) 
 
Grind them up to make your own… 
 
 Pistachio butter (You know, like peanut butter.) 
 
Or… 
 
 Eat them just as they are! 
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D. Physical Activity Questionnaire
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E. Hunger/Satiety Scale 
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F. Visual Analog Scale 
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G. Unusual Diet Diary 
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H. Informed Consent Form 
 
 114 
 
 
 115 
 
 
 
 116 
 
 
 
